TY - JOUR A1 - Akhrif, Atae A1 - Romanos, Marcel A1 - Domschke, Katharina A1 - Schmitt-Boehrer, Angelika A1 - Neufang, Susanne T1 - Fractal Analysis of BOLD Time Series in a Network Associated With Waiting Impulsivity JF - Frontiers in Physiology N2 - Fractal phenomena can be found in numerous scientific areas including neuroscience. Fractals are structures, in which the whole has the same shape as its parts. A specific structure known as pink noise (also called fractal or 1/f noise) is one key fractal manifestation, exhibits both stability and adaptability, and can be addressed via the Hurst exponent (H). FMRI studies using H on regional fMRI time courses used fractality as an important characteristic to unravel neural networks from artificial noise. In this fMRI-study, we examined 103 healthy male students at rest and while performing the 5-choice serial reaction time task. We addressed fractality in a network associated with waiting impulsivity using the adaptive fractal analysis (AFA) approach to determine H. We revealed the fractal nature of the impulsivity network. Furthermore, fractality was influenced by individual impulsivity in terms of decreasing fractality with higher impulsivity in regions of top-down control (left middle frontal gyrus) as well as reward processing (nucleus accumbens and anterior cingulate cortex). We conclude that fractality as determined via H is a promising marker to quantify deviations in network functions at an early stage and, thus, to be able to inform preventive interventions before the manifestation of a disorder. KW - fMRI KW - Hurst Exponent KW - frontal cortex KW - nucleus accumbens KW - biomarker KW - impulse control disorders Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-189191 SN - 1664-042X VL - 9 ER - TY - THES A1 - Albantakis, Laura Irena Teresa T1 - Periphere Expression von Brain Derived Neurotrophic Factor bei Kindern und Jugendlichen mit Autismus-Spektrum-Störungen T1 - Altered peripheral expression of brain derived neurotrophic factor in blood of children and adolescents with autism spectrum disorders N2 - Neurotrophine beeinflussen durch die Modulation von Prozessen wie Zellproliferation, -migration, Apoptose und Synapsenbildung entscheidend die neuronale Plastizität. Sie gelten deshalb als Kandidatengene neuronaler Entwicklungsstörungen wie Autismus-Spektrum-Störungen (ASS). Die vorgelegte Arbeit zielt auf die weitere Klärung der Rolle von Brain Derived Neurotrophic Factor (BDNF) bei der Ätiopathophysiologie der ASS durch Expressionsanalysen im Blut als potenziellem Surrogat zentralnervöser Prozesse. In gut charakterisierten ASS-Stichproben und - neben gesunden Kontrollprobanden - einer klinischen Kontrollgruppe von Patienten mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) wurde die BDNF-mRNA-Expression in Vollblut sowie BDNF-Proteinserumkonzentrationen untersucht. Zusätzlich wurden mögliche Einflussfaktoren auf die BDNF-Werte wie Alter, IQ, autismusspezifische Symptomatik, Komorbidität und Medikation analysiert. In einer ersten Stichprobe (ASS-Patienten versus gesunde Kontrollen) wurden signifikant erniedrigte BDNF-Serumkonzentrationen in der Patientengruppe mittels Enzyme-Linked-Immunosorbent-Assay gemessen (p = 0,040). In einer zweiten unabhängigen Stichprobe (Patienten mit ASS, Patienten mit ADHS und gesunde Kontrollen) wurde auf mRNA-Ebene mittels quantitativer Real-Time-Polymerasekettenreaktion ebenfalls ein signifikanter Gruppenunterschied ermittelt mit erniedrigter BDNF-Expression in der ASS-Gruppe im Vergleich zu gesunder Kontrollgruppe (p = 0,011), sowie einem Trend zu erniedrigten BDNF-Werten bei ADHS-Patienten im Vergleich zu gesunden Probanden (p = 0,097). Des Weiteren wurde eine signifikante negative Korrelation zwischen Alter und BDNF-mRNA-Expression bei Patienten mit ASS sowie eine positive Korrelation von Alter und BDNF-Serumkonzentrationen bei gesunden Kontrollen gemessen. Auch korrelierten die BDNF-Werte im Serum mit der Ausprägung des autistischen Phänotyps. In einer Subgruppe der ADHS-Patienten wurde kein Einfluss von Psychostimulanzien auf die BDNF-mRNA-Expression gemessen. Der Einbezug größerer Stichproben sowie die systematische Erfassung weiterer potenzieller Einflussfaktoren auf die BDNF-Expression (wie pubertärer Entwicklungsstand bzw. Geschlechtshormonkonzentrationen) könnten in zukünftigen Studien zu einer weiteren Klärung der pathophysiologischen Rolle von BDNF bei Kindern und Jugendlichen mit ASS beitragen. N2 - Neurotrophins impact on neuronal plasticity by modulating processes such as cell proliferation, cell migration, apoptosis and synaptic plasticity. Therefore, they are regarded as candidate genes for neurodevelopmental disorders such as autism spectrum disorders (ASD). The following work aims at further clarifying the role of brain derived neurotrophic factor (BDNF) in the pathophysiology of ASD by expression analyses in blood as a potential surrogate for BDNF effects observed in the central nervous system. BDNF mRNA expression in whole blood and BDNF serum concentrations were analyzed in well characterized samples of ASD patients, healthy controls, and a clinical control group of patients with attention deficit hyperactivity disorder (ADHD). In addition, potential modulating factors such as age, IQ, autistic phenotype, comorbidity and medication were further investigated. In a first project (ASD patients vs. healthy controls) significantly lower BDNF serum concentrations in the ASD group were observed via enzyme-linked immunosorbent assay (p = 0.040). In a second independent sample and project (patients with ASS, patients with ADHD, and healthy controls), BDNF mRNA expression was analyzed using quantitative real time polymerase chain reaction. Also in this sample, a significant group difference was found with lower BDNF expression in the ASD group compared to the health controls (p = 0.011). Moreover, a trend of decreased BDNF mRNA levels was observed for patients with ADHD in comparison to the normally developing controls (p = 0.097). Furthermore, with regard to potential influencing factors, we found a significant negative correlation between age and BDNF mRNA expression in patients with ASD, as well as a positive correlation between age and BDNF serum concentrations in healthy controls. A positive correlation was moreover detected between the serum BDNF concentrations and autistic phenotype. Testing a sub-group of ADHD patients, no significant influence of stimulants was observed on BDNF mRNA expression. In future studies, bigger sample sizes as well as a systematic assessment of other factors that potentially influence BDNF expression (like pubertal developmental status or concentration of sex hormones) could further clarify the pathophysiological role of BDNF in children and adolescents with ASD. KW - brain derived neurotrophic factor KW - Brain-derived neurotrophic factor KW - Autismus-Spektrum-Störung KW - Autismus-Spektrum-Störung KW - periphere Expression Brain-derived neurotrophic factor KW - peripheral expression KW - autism spectrum disorder Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-157172 ET - um 2 Leerseiten korrigierte Ausgabe ER - TY - THES A1 - Albantakis, Laura Irena Teresa T1 - Periphere Expression von Brain Derived Neurotrophic Factor bei Kindern und Jugendlichen mit Autismus-Spektrum-Störungen T1 - Altered peripheral expression of brain derived neurotrophic factor in blood of children and adolescents with autism spectrum disorders N2 - Neurotrophine beeinflussen durch die Modulation von Prozessen wie Zellproliferation, -migration, Apoptose und Synapsenbildung entscheidend die neuronale Plastizität. Sie gelten deshalb als Kandidatengene neuronaler Entwicklungsstörungen wie Autismus-Spektrum-Störungen (ASS). Die vorgelegte Arbeit zielt auf die weitere Klärung der Rolle von Brain Derived Neurotrophic Factor (BDNF) bei der Ätiopathophysiologie der ASS durch Expressionsanalysen im Blut als potenziellem Surrogat zentralnervöser Prozesse. In gut charakterisierten ASS-Stichproben und - neben gesunden Kontrollprobanden - einer klinischen Kontrollgruppe von Patienten mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) wurde die BDNF-mRNA-Expression in Vollblut sowie BDNF-Proteinserumkonzentrationen untersucht. Zusätzlich wurden mögliche Einflussfaktoren auf die BDNF-Werte wie Alter, IQ, autismusspezifische Symptomatik, Komorbidität und Medikation analysiert. In einer ersten Stichprobe (ASS-Patienten versus gesunde Kontrollen) wurden signifikant erniedrigte BDNF-Serumkonzentrationen in der Patientengruppe mittels Enzyme-Linked-Immunosorbent-Assay gemessen (p = 0,040). In einer zweiten unabhängigen Stichprobe (Patienten mit ASS, Patienten mit ADHS und gesunde Kontrollen) wurde auf mRNA-Ebene mittels quantitativer Real-Time-Polymerasekettenreaktion ebenfalls ein signifikanter Gruppenunterschied ermittelt mit erniedrigter BDNF-Expression in der ASS-Gruppe im Vergleich zu gesunder Kontrollgruppe (p = 0,011), sowie einem Trend zu erniedrigten BDNF-Werten bei ADHS-Patienten im Vergleich zu gesunden Probanden (p = 0,097). Des Weiteren wurde eine signifikante negative Korrelation zwischen Alter und BDNF-mRNA-Expression bei Patienten mit ASS sowie eine positive Korrelation von Alter und BDNF-Serumkonzentrationen bei gesunden Kontrollen gemessen. Auch korrelierten die BDNF-Werte im Serum mit der Ausprägung des autistischen Phänotyps. In einer Subgruppe der ADHS-Patienten wurde kein Einfluss von Psychostimulanzien auf die BDNF-mRNA-Expression gemessen. Der Einbezug größerer Stichproben sowie die systematische Erfassung weiterer potenzieller Einflussfaktoren auf die BDNF-Expression (wie pubertärer Entwicklungsstand bzw. Geschlechtshormonkonzentrationen) könnten in zukünftigen Studien zu einer weiteren Klärung der pathophysiologischen Rolle von BDNF bei Kindern und Jugendlichen mit ASS beitragen. N2 - Neurotrophins impact on neuronal plasticity by modulating processes such as cell proliferation, cell migration, apoptosis and synaptic plasticity. Therefore, they are regarded as candidate genes for neurodevelopmental disorders such as autism spectrum disorders (ASD). The following work aims at further clarifying the role of brain derived neurotrophic factor (BDNF) in the pathophysiology of ASD by expression analyses in blood as a potential surrogate for BDNF effects observed in the central nervous system. BDNF mRNA expression in whole blood and BDNF serum concentrations were analyzed in well characterized samples of ASD patients, healthy controls, and a clinical control group of patients with attention deficit hyperactivity disorder (ADHD). In addition, potential modulating factors such as age, IQ, autistic phenotype, comorbidity and medication were further investigated. In a first project (ASD patients vs. healthy controls) significantly lower BDNF serum concentrations in the ASD group were observed via enzyme-linked immunosorbent assay (p = 0.040). In a second independent sample and project (patients with ASS, patients with ADHD, and healthy controls), BDNF mRNA expression was analyzed using quantitative real time polymerase chain reaction. Also in this sample, a significant group difference was found with lower BDNF expression in the ASD group compared to the health controls (p = 0.011). Moreover, a trend of decreased BDNF mRNA levels was observed for patients with ADHD in comparison to the normally developing controls (p = 0.097). Furthermore, with regard to potential influencing factors, we found a significant negative correlation between age and BDNF mRNA expression in patients with ASD, as well as a positive correlation between age and BDNF serum concentrations in healthy controls. A positive correlation was moreover detected between the serum BDNF concentrations and autistic phenotype. Testing a sub-group of ADHD patients, no significant influence of stimulants was observed on BDNF mRNA expression. In future studies, bigger sample sizes as well as a systematic assessment of other factors that potentially influence BDNF expression (like pubertal developmental status or concentration of sex hormones) could further clarify the pathophysiological role of BDNF in children and adolescents with ASD. KW - Autismus-Spektrum-Störung KW - Brain-derived neurotrophic factor KW - Periphere Expression KW - Autismus-Spektrum-Störung KW - Brain-derived neurotrophic factor KW - Peripheral expression KW - brain derived neurotrophic factor KW - autism spectrum disorder Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-106666 ER - TY - THES A1 - Andritschky, Christoph T1 - Verhaltensauffälligkeiten und elterliche Stressbelastung bei 22q11.2- Deletionssyndrom - eine Längsschnittstudie T1 - Behaviour problems and parental stress in 22q11.2 deletion syndrome - a longitudinal study N2 - Fragestellung: Querschnittstudien konnten bei Kindern und Jugendlichen mit Deletion 22q11.2 eine Tendenz zu mit dem Alter zunehmenden Verhaltensauffälligkeiten verbunden mit einem Anstieg der elterlichen Stressbelastung zeigen. Die aktuelle Längsschnittstudie sollte diese Ergebnisse überprüfen. Methodik: Mit Hilfe der deutschen Selbsthilfegruppe KiDS 22q11 wurden alle Hauptbezugspersonen, die bereits vier Jahre zuvor an einer Befragung zu Verhaltensauffälligkeiten und Stress teilgenommen hatten, anonymisiert um die Bearbeitung verschiedener Fragebögen gebeten. Ergebnisse: 59 von 94 Hauptbezugspersonen sandten ausgefüllte Fragebögen zurück. Dabei wurden 54% aller Kinder und Jugendlichen (29 männlich, 30 weiblich, im Alter von 5,8 bis 18,9 Jahren, Mittelwert: 10,8 Jahre) von ihren Hauptbezugspersonen als verhaltensauffällig eingestuft (Gesamtwert Child Behavior Checklist [CBCL] bzw. Fragebogen über das Verhalten junger Erwachsener [YABCL]). In nahezu allen Bereichen der Child Behavior Checklist, mit der die Erfassung der Verhaltensauffälligkeiten erfolgte, kam es im Verlauf zu einer statistisch signifikanten Zunahme. Auch stieg die Stressbelastung der Hauptbezugspersonen, erfasst mittels Fragebogen Soziale Orientierungen von Eltern behinderter Kinder, im Vergleich zur Erstbefragung signifikant an, ohne dass sich jedoch die Lebenszufriedenheit signifikant verändert hätte. Das Ausmaß der elterlichen Stressbelastung korrelierte signifikant mit dem Gesamtproblemwert der CBCL. Schlussfolgerungen: Die Ergebnisse der aktuellen Längsschnittstudie bestätigen die Befunde früherer Querschnittuntersuchungen hinsichtlich Verhaltensauffälligkeiten bei Kindern und Jugendlichen mit Deletion 22q11.2. Aufgrund der zunehmenden Verhaltensprobleme und der damit einhergehenden Stressbelastung ist mit einem erhöhten Beratungsbedarf der Hauptbezugspersonen und einer zunehmenden Behandlungsbedürftigkeit der Patienten zu rechnen. N2 - Backround: Cross-sectional studies have shown a tendency to age increasing behaviour problems associated with an increase in parental stress in children and adolescents with 22q11.2 deletion. The current longitudinal study should review these results. Method: Using the German self-help group KiDS 22q11 all main caregivers who had four years earlier participated in a survey about behaviour problems and stress, were asked anonymously to answer again different questionnaires. Results: 59 of 94 primary caregivers sent back the completed questionnaires. 54% (29 male, 30 female, aged 5.8 to 18.9 years, mean 10.8 years) were classified clinical for behaviour problems by their primary caregivers (total problems scale of Child Behavior Checklist [CBCL] resp. Young Adult Behavior Checklist [YABCL]). In almost all areas of the Child Behavior Checklist occurred in the course a statistically significant increase. The stress of the main caregivers rose, recorded by questionnaire Social orientations of parents of disabled children, compared to the initial survey significantly, without any significantly change in life satisfaction. The extent of parental stress was significantly correlated with the total problems score of the CBCL. Conclusion: The results of this longitudinal study confirm the findings of previous cross-sectional studies on behaviour problems in children and adolescents with 22q11.2 deletion. Due to the increasing behaviour problems and the associated stress is to be expected with an increased need for counseling the main caregivers and an increasing need for treatment of patients. KW - 22q11 KW - Mikrodeletionssyndrom KW - DiGeorge-Syndrom KW - Längsschnittuntersuchung KW - Verhaltensauffälligkeiten KW - 22q11.2- Deletionssyndrom KW - Verhaltensauffälligkeiten KW - Elterliche Stressbelastung KW - Längsschnittstudie KW - behaviour problems KW - parental stress KW - longitudinal study Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-110513 ER - TY - JOUR A1 - Aster, H-C A1 - Evdokimov, D. A1 - Braun, A. A1 - Üçeyler, N. A1 - Sommer, C. T1 - Analgesic Medication in Fibromyalgia Patients: A Cross-Sectional Study JF - Pain Research and Management N2 - There is no approved drug for fibromyalgia syndrome (FMS) in Europe. In the German S3 guideline, amitriptyline, duloxetine, and pregabalin are recommended for temporary use. The aim of this study was to cross-sectionally investigate the current practice of medication in FMS patients in Germany. We systematically interviewed 156 patients with FMS, while they were participating in a larger study. The patients had been stratified into subgroups with and without a decrease in intraepidermal nerve fiber density. The drugs most commonly used to treat FMS pain were nonsteroidal anti-inflammatory drugs (NSAIDs) (41.0% of all patients), metamizole (22.4%), and amitriptyline (12.8%). The most frequent analgesic treatment regimen was “on demand” (53.9%), during pain attacks, while 35.1% of the drugs were administered daily and the remaining in other regimens. Median pain relief as self-rated by the patients on a numerical rating scale (0–10) was 2 points for NSAIDS, 2 for metamizole, and 1 for amitriptyline. Drugs that were discontinued due to lack of efficacy rather than side effects were acetaminophen, flupirtine, and selective serotonin reuptake inhibitors. Reduction in pain severity was best achieved by NSAIDs and metamizole. Our hypothesis that a decrease in intraepidermal nerve fiber density might represent a neuropathic subtype of FMS, which would be associated with better effectiveness of drugs targeting neuropathic pain, could not be confirmed in this cohort. Many FMS patients take “on-demand” medication that is not in line with current guidelines. More randomized clinical trials are needed to assess drug effects in FMS subgroups. KW - Fibromyalgia KW - analgesic medication KW - study Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300578 VL - 2022 ER - TY - JOUR A1 - Aster, Hans-Christoph A1 - Evdokimov, Dimitar A1 - Braun, Alexandra A1 - Üçeyler, Nurcan A1 - Kampf, Thomas A1 - Pham, Mirko A1 - Homola, György A. A1 - Sommer, Claudia T1 - CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement JF - Scientific Reports N2 - We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials. KW - fibromyalgia syndrome KW - CNS imaging KW - peripheral nerve involvement Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300562 VL - 12 IS - 1 ER - TY - JOUR A1 - Aster, Hans-Christoph A1 - Romanos, Marcel A1 - Walitza, Susanne A1 - Gerlach, Manfred A1 - Mühlberger, Andreas A1 - Rizzo, Albert A1 - Andreatta, Marta A1 - Hasenauer, Natalie A1 - Hartrampf, Philipp E. A1 - Nerlich, Kai A1 - Reiners, Christoph A1 - Lorenz, Reinhard A1 - Buck, Andreas K. A1 - Deserno, Lorenz T1 - Responsivity of the striatal dopamine system to methylphenidate — A within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder JF - Frontiers in Psychiatry N2 - Background: Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning. Methods Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH. Results On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04). Conclusion Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity. KW - methylphenidate KW - attention deficit/hyperactivity disorder (ADHD) KW - striatum KW - single photon emission computed tomography (SPECT) KW - responsivity KW - caudate nucleus KW - dopamine transporter (DAT) Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270862 SN - 1664-0640 VL - 13 ER - TY - THES A1 - Balsam, Anne T1 - Untersuchung der Vigilanzregulation von Kindern und Jugendlichen mit der Diagnose Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) verglichen mit alters- und geschlechtsgleichen gesunden Kontrollen T1 - Vigilance regulation of children and youth with ADHD in comparison to healthy controls N2 - ADHS-Patienten im Alter von 8-12 Jahren wurde ein Ruhe-EEG von 10 Minuten jeweils mediziert sowie medikamentennüchtern abgeleitet und mittels des Vigilanzalgorithmus Leipzig von Hegerl und Hensch (2012) ausgewertet und den bei gesunden Kontrollkindern gleichen Alters gemessenen EEG-Frequenzen nach Auswertung durch die gleiche Methode gegenübergestellt. N2 - Comparison of EEG-vigilance stages of children and youth from 8 to 12 years with ADHD (with and without medication)and healthy controls. KW - VIGALL KW - ADHS KW - EEG KW - Vigilanz KW - Stimulanzien KW - Kinder- und Jugendpsychiatrie Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-192440 ER - TY - THES A1 - Barthel, Dominik T1 - Komorbide Störungen bei Kindern und Jugendlichen mit ADHS: Vergleich des vorwiegend unaufmerksamen Subtypus mit dem Mischtypus nach DSM-IV T1 - Comorbidity of ADHD in children and adolescents: comparison of the predominantly inattentive and the combined subtypes defined by DSM-IV criteria N2 - In der vorliegenden Arbeit wurde ein Vergleich der klinischen Erscheinungsbilder des vorwiegend unaufmerksamen Subtypus mit dem Mischtypus der ADHS nach DSM-IV-Kriterien vorgenommen. Ausgehend von Ergebnissen vorangehender Studien wurde der Frage nachgegangen, ob die Subtypen unterschiedliche Verteilungsmuster komorbider Störungen zeigen. So wurde überprüft, ob der Mischtypus insgesamt schwerer von Komorbidität betroffen ist und häufiger externale Störungen (Störung mit oppositionellem Trotzverhalten bzw. Sozialverhaltensstörungen) aufweist. Beim vorwiegend unaufmerksamen Subtypus hingegen wurde eine stärkere Belastung mit internalen Störungsbildern (Angst- und depressive Störungen) und der Lese- Rechtschreibstörung angenommen. Der Stichprobenumfang (n=124) erlaubte zusätzlich eine getrennte Betrachtung der Geschlechter sowie von Kindern und Jugendlichen. Dadurch sollten geschlechts- und entwicklungsabhängige Einflüsse aufgezeigt werden, die in der Literatur bisher unberücksichtigt blieben. Erstmals wurden in dieser Untersuchung neben den Tic- und den Ausscheidungsstörungen auch weitere psychiatrische Diagnosen (Substanzmissbrauch, Zwangs- und Essstörungen sowie Belastungsreaktionen) mitberücksichtigt, um empirische Erkenntnisse über eine potentiell differente Assoziation derselben mit den ADHS-Subtypen zu gewinnen. Zur Beurteilung der klinischen Subtypen wurde mit allen Kindern und Jugendlichen sowie deren Eltern ein halbstrukturiertes Interview durchgeführt (K-SADS-PL) und somit die entsprechenden psychiatrischen Lebenszeitdiagnosen der Probanden erhoben. Zur dimensionalen Beurteilung der psychischen Auffälligkeiten der Kinder wurde von den Eltern ein Breitbandfragebogen (CBCL) ausgefüllt; zusätzlich schätzten die Probanden ihre aktuelle depressive Symptomatik mittels eines Selbstbeurteilungsbogens ein. Die ADHS-Symptomatik wurde sowohl klinisch als auch anhand eines störungsspezifischen Lehrerfragebogens (FBB-HKS) beurteilt. Durch diese multimodale Vorgehensweise konnten informanten- und instrumentenabhängige Verzerrungen der Ergebnisse minimiert werden. Alle Ergebnisse der kategorialen Diagnostik mittels K-SADS-PL wurden durch die dimensionale Auswertung des Elternurteils (CBCL) gestützt, was auf eine hohe Validität der durchgeführten Interviews verweist. Die Variablen Alter, Geschlecht sowie kognitives Leistungsniveau wurden im Rahmen dieser Dissertationsarbeit erstmals in einer Studie zur Komorbidität der ADHS-Subtypen ausführlich untersucht. Zudem wurden diese im Rahmen der Parallelisierung der Vergleichsgruppen berücksichtigt, ein Vorgehen was sich aus den in der Literatur beschriebenen Interaktionen dieser Variablen mit komorbiden Störungen ergibt. Des Weiteren ist die im Rahmen der Untersuchung durchgeführte differenzierte Leistungstestung der schriftsprachlichen Fertigkeiten bei einer ADHS-Population als Neuerung zu betrachten, da bisher noch keine Untersuchung zur differenten Komorbidität der ADHS-Subtypen mit Legasthenie durchgeführt wurde. Es konnte gezeigt werden, dass die genannten Faktoren signifikanten Einfluss auf die Ergebnisse der Komorbiditätsforschung haben, weshalb deren Berücksichtigung in zukünftigen Forschungsprojekten dringend zu empfehlen ist. Diese Studie widerlegt die Annahme, dass sich die ADHS bei den Geschlechtern in gleicher Weise manifestiert: Nach unseren Ergebnissen ist davon auszugehen, dass eine höhere komorbide Gesamtbelastung des Mischtypus im Vergleich mit dem vorwiegend unaufmerksamen Subtypus nur beim männlichen Geschlecht besteht. Bei Mädchen ist ADHS-U ebenso stark von Komorbidität betroffen wie ADHS-M; der unaufmerksame Subtypus zeigte hier nach Elternurteil sogar stärkere Probleme im sozialen Bereich als der Mischtypus. Eine höhere Rate an externalisierenden Störungsbildern beim Mischtypus war für Gesamtstichprobe und für die männliche Stichprobe nachzuweisen – bei den weiblichen Probanden waren die Subtypen diesbezüglich gleich schwer betroffen. Die im Rahmen dieser Studie gefundenen hohen Komorbiditätsraten mit affektiven Störungen decken sich mit der Annahme, dass eine Assoziation zwischen Unaufmerksamkeit und depressiver Symptomatik besteht. Ob dies zu einer unterschiedlichen Belastung der von Unaufmerksamkeit gekennzeichneten Subtypen ADHS-U und ADHS-M führt, kann nach bisheriger Datenlage nicht beantwortet werden. Hinweise darauf, dass ADHS-U stärker mit depressiven Störungen belastet ist, ergaben sich in unserer Stichprobe in der Altersgruppe unter 12 Jahren. Im Kindesalter war der vorwiegend unaufmerksame Subtypus zudem signifikant häufiger von Lese-Rechtschreibstörung betroffen als der Mischtypus; beide Ergebnisse waren in der Altersgruppe zwischen 12 und 17 Jahren nicht nachweisbar. In Zusammenschau mit Voruntersuchungen lassen sich diese Befunde im Sinne einer heterogenen ADHS-U-Gruppe im Jugendalter deuten: Sie setzt sich sowohl aus Patienten zusammen, die seit Kindheit vorwiegend unaufmerksam klassifiziert wurden sowie aus solchen, die ursprünglich die Kriterien für ADHS-M erfüllten und als Jugendliche – nach entwicklungsbedingtem Rückgang der motorischen Hyperaktivität – ADHS-U zugeordnet werden. Die höchste Rate an affektiven Störungen in unserer Stichprobe war für die weibliche ADHS-U-Gruppe nachzuweisen; diese war auf allen internalen Skalen der CBCL signifikant stärker betroffen als Mädchen vom Mischtypus. Für die Angststörungen zeigte sich hingegen beim Mischtypus eine signifikant stärkere Betroffenheit des männlichen Geschlechts; im Vergleich mit männlichen Versuchsteilnehmern des vorwiegend unaufmerksamen Subtypus deutete sich ein entsprechender Unterschied an. Insofern ergeben sich aus der vorliegenden Untersuchung neue Hypothesen, bei denen besonders die gefundenen Interaktionen zwischen ADHS-Subtyp und Geschlecht und die Entwicklungsaspekte zu berücksichtigen sind. N2 - Aim of work this comparison of the phenotypes of the predominantly inattentive and the combined subtypes of ADHD defined by DSM-IV criteria with a main focus on lifetime-comorbidity. We used a multi-method and multi-informant design to evaluate differences in the course from childhood to adolescence and those between male and female patients. KW - ADHS KW - Subtypen KW - Komorbidität KW - Geschlechter KW - ADHS KW - Subtypen KW - Komorbidität KW - Geschlechter KW - adhd KW - subtypes KW - inattentive KW - comorbidity KW - gender Y1 - 2009 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-46484 ER - TY - JOUR A1 - Beierle, Felix A1 - Schobel, Johannes A1 - Vogel, Carsten A1 - Allgaier, Johannes A1 - Mulansky, Lena A1 - Haug, Fabian A1 - Haug, Julian A1 - Schlee, Winfried A1 - Holfelder, Marc A1 - Stach, Michael A1 - Schickler, Marc A1 - Baumeister, Harald A1 - Cohrdes, Caroline A1 - Deckert, Jürgen A1 - Deserno, Lorenz A1 - Edler, Johanna-Sophie A1 - Eichner, Felizitas A. A1 - Greger, Helmut A1 - Hein, Grit A1 - Heuschmann, Peter A1 - John, Dennis A1 - Kestler, Hans A. A1 - Krefting, Dagmar A1 - Langguth, Berthold A1 - Meybohm, Patrick A1 - Probst, Thomas A1 - Reichert, Manfred A1 - Romanos, Marcel A1 - Störk, Stefan A1 - Terhorst, Yannik A1 - Weiß, Martin A1 - Pryss, Rüdiger T1 - Corona Health — A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic JF - International Journal of Environmental Research and Public Health N2 - Physical and mental well-being during the COVID-19 pandemic is typically assessed via surveys, which might make it difficult to conduct longitudinal studies and might lead to data suffering from recall bias. Ecological momentary assessment (EMA) driven smartphone apps can help alleviate such issues, allowing for in situ recordings. Implementing such an app is not trivial, necessitates strict regulatory and legal requirements, and requires short development cycles to appropriately react to abrupt changes in the pandemic. Based on an existing app framework, we developed Corona Health, an app that serves as a platform for deploying questionnaire-based studies in combination with recordings of mobile sensors. In this paper, we present the technical details of Corona Health and provide first insights into the collected data. Through collaborative efforts from experts from public health, medicine, psychology, and computer science, we released Corona Health publicly on Google Play and the Apple App Store (in July 2020) in eight languages and attracted 7290 installations so far. Currently, five studies related to physical and mental well-being are deployed and 17,241 questionnaires have been filled out. Corona Health proves to be a viable tool for conducting research related to the COVID-19 pandemic and can serve as a blueprint for future EMA-based studies. The data we collected will substantially improve our knowledge on mental and physical health states, traits and trajectories as well as its risk and protective factors over the course of the COVID-19 pandemic and its diverse prevention measures. KW - mobile health KW - ecological momentary assessment KW - digital phenotyping KW - longitudinal studies KW - mobile crowdsensing Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242658 SN - 1660-4601 VL - 18 IS - 14 ER - TY - JOUR A1 - Bender, Stephan A1 - Resch, Franz A1 - Klein, Christoph A1 - Renner, Tobias A1 - Fallgatter, Andreas J. A1 - Weisbrod, Matthias A1 - Romanos, Marcel T1 - Influence of Stimulant Medication and Response Speed on Lateralization of Movement-Related Potentials in Attention-Deficit/Hyperactivity Disorder JF - PLoS One N2 - Background: Hyperactivity is one of the core symptoms in attention deficit hyperactivity disorder (ADHD). However, it remains unclear in which way the motor system itself and its development are affected by the disorder. Movement-related potentials (MRP) can separate different stages of movement execution, from the programming of a movement to motor post-processing and memory traces. Pre-movement MRP are absent or positive during early childhood and display a developmental increase of negativity. Methods: We examined the influences of response-speed, an indicator of the level of attention, and stimulant medication on lateralized MRP in 16 children with combined type ADHD compared to 20 matched healthy controls. Results: We detected a significantly diminished lateralisation of MRP over the pre-motor and primary motor cortex during movement execution (initial motor potential peak, iMP) in patients with ADHD. Fast reactions (indicating increased visuo-motor attention) led to increased lateralized negativity during movement execution only in healthy controls, while in children with ADHD faster reaction times were associated with more positive amplitudes. Even though stimulant medication had some effect on attenuating group differences in lateralized MRP, this effect was insufficient to normalize lateralized iMP amplitudes. Conclusions: A reduced focal (lateralized) motor cortex activation during the command to muscle contraction points towards an immature motor system and a maturation delay of the (pre-) motor cortex in children with ADHD. A delayed maturation of the neuronal circuitry, which involves primary motor cortex, may contribute to ADHD pathophysiology. KW - deficit-hyperactivity disorder KW - anticipatory mechanisms KW - motor preparation KW - TIC disorder KW - children KW - ADHD KW - methylphenidate KW - contingent negative-variation KW - continuous performance-test KW - slow cortical potentials Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135262 VL - 7 IS - 6 ER - TY - THES A1 - Bennetz, Maike T1 - Auffälligkeiten in Gedächtnisfunktionen bei Kindern mit Lese-Rechtschreibschwäche T1 - Dyslexic Children: Special Aspects of Memory Functions N2 - Ziel der Studie war die Exploration von Funktionen des Kurzzeitgedächtnisses bei lese-rechtschreibschwachen Kindern (LRS) im Vergleich zu einer schriftsprachlich normal entwickelten Kontrollgruppe (KG). Gedächtnisfunktionen sollten im Hinblick auf Entwicklungsveränderungen über eine Altersspanne von acht bis dreizehn Jahren untersucht werden. Bei einem möglichen Gedächtnisdefizit sollte überprüft werden, ob dieses sich nur bei schriftsprachähnlichem Material äußerte oder ob es sich um ein allgemeineres Defizit handelte. Insgesamt 65 lese-rechtschreibschwache und schriftsprachlich normal entwickelte Kinder der Altersgruppen 8-9 Jahre, 10-11 Jahre und 12-13 Jahre wurden Aufgaben zur Gedächtnisspanne, zur Benennungsgeschwindigkeit und zur Suchrate unterzogen. In den Aufgaben zur Gedächtnisspanne und zur Benennungsgeschwindigkeit zeigten die lese-rechtschreibschwachen Kinder deutlich schlechtere Leistungen als die Kontrollgruppe, und beide untersuchten Gruppen verbesserten sich in ihren Leistungen mit ansteigendem Alter. Hinweise für ein schriftsprachorientiertes Defizit im Falle der Rechtschreibschwachen ließen sich den Aufgaben zur Gedächtnisspanne und zur Suchrate entnehmen. Zusammenfassend bestätigen die vorliegenden Ergebnisse Defizite in Funktionen des Kurzzeitgedächtnisses bei LRS. Über die untersuchte Altersspanne hinweg kam es nicht zu einer Annäherung der Leistungen der Rechtschreibschwachen an die der Kontrollgruppe, was für ein bleibendes Defizit im Fall der LRS spricht. Um zu eindeutigen Ergebnissen hinsichtlich der Schriftsprachabhängigkeit der Gedächtnisdefizite bei LRS kommen zu können, müssen weitere Studien abgewartet werden. N2 - The aim of the study was to investigate short term memory functions in dyslexic children compared to a control group with normally developed written language skills. Memory functions were to be examined with regard to developmental alterations within an age range of eight to thirteen years. In case of a detected possible memory deficiency, it had to be tested if this became manifest only with material resembling written language or if it represented a more general deficiency. A total of 65 dyslexic and control children with normally developed written language skills of age groups 8-9, 10-11, and 12-13 years were tested for memory span, naming speed and search rate. Achievements in memory span and naming speed of the dyslexic children were distinctly worse than those of the controls. Both examined groups improved with age. The results of memory span and search rate testings provide hints towards a written language related deficiency. In summary the presented data confirm deficits in short term memory functions of dyslexic children. In the examined age range the achievements of dyslexics and controls did not approach with rising age, suggesting a permanent deficit of the dyslexic group. Further studies are needed to examine if dyslexia related memory deficiencies are restricted to written language skills. KW - Lese-Rechtschreibschwäche KW - Gedächtnis KW - Gedächtnisspanne KW - Benennungsgeschwindigkeit KW - Suchrate KW - dyslexia KW - memory KW - memory-span KW - naming-speed KW - search-rate Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-10941 ER - TY - THES A1 - Beyer, Regina-Maria T1 - Kognitive und psychosoziale Faktoren bei Kindern mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) und Lese-Rechtschreibstörung T1 - Kognitive and social factors at children with ADHDS and Dyslexia. N2 - Zusammenfassung Die retrospektive Datenanalyse dreier Gruppen à 20 Kinder im Alter von 8-12 Jahren mit hyperkinetischen Störungen und/oder einer Lese-Rechtschreibstörung der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und Psychotherapie der Universität Würzburg ergab die nachfolgenden Ergebnisse. Die Ergebnisse der vorliegenden Studie finden sich in der Literatur wieder. Kognitive Fähigkeiten Im kognitiven Bereich fanden sich wenige Unterschiede zwischen den Gruppen. Nachteile ergaben sich aus der Tatsache heraus, dass die Studie retrospektiv durchgeführt wurde und die Fallzahlen daher teils sehr klein waren. Sozial-emotionaler Bereich Für den sozial-emotionalen Bereich fanden sich plausible Ergebnisse. Den Kindern mit einer Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) waren vermehrt expansive Verhaltensweisen nachzuweisen wie zum Beispiel ein gestörtes Regelverhalten, oppositionelles Verhalten, Aggressivität, Probleme mit Gleichaltrigen, Einzelgängerdasein oder Auffälligkeiten in der Vorschule. Bei den Kindern mit Lese-Rechtschreibstörung fanden sich vielmehr introversive Merkmale wie beispielsweise eine emotionale Störung, ein mangelndes Selbstwertgefühl oder Schulangst. Psychosoziale Situation Die Auswertung des Psychosozialen Bereiches der Kinder mittels Achse V und VI des multiaxialen Klassifikationsschemas für psychische Störungen des Kindes- und Jugendalters ergab eine Belastung der Kinder mit hyperkinetischen Störungen vor allem durch eine abweichende Elternsituation und eine negativ veränderte familiäre Beziehung durch neue Familienmitglieder. Die Kinder mit Lese-Rechtschreibstörung waren besonders betroffen von einer chronischen zwischenmenschlichen Belastung in Zusammenhang mit der Schule sowie von der Herabsetzung der Selbstachtung. N2 - Kognitive and social factors at children with ADHDS and Dyslexia. Three groups of 20 children have been analysed. In children with ADHDS we found for example a higher rate of aggressivity. In dyslexic children we found for example showed less self-esteem. No significant differences regarding the cognitive factors. KW - ADHS KW - LRS KW - Kinderpsychiatrie KW - Jugendpsychiatrie KW - ADHDS KW - Dyslexia KW - Children Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-18932 ER - TY - JOUR A1 - Biehl, Stefanie C. A1 - Dresler, Thomas A1 - Reif, Andreas A1 - Scheuerpflug, Peter A1 - Deckert, Jürgen A1 - Herrmann, Martin J. T1 - Dopamine Transporter (DAT1) and Dopamine Receptor D4 (DRD4) Genotypes Differentially Impact on Electrophysiological Correlates of Error Processing JF - PLoS One N2 - Recent studies as well as theoretical models of error processing assign fundamental importance to the brain's dopaminergic system. Research about how the electrophysiological correlates of error processing—the error-related negativity (ERN) and the error positivity (Pe)—are influenced by variations of common dopaminergic genes, however, is still relatively scarce. In the present study, we therefore investigated whether polymorphisms in the DAT1 gene and in the DRD4 gene, respectively, lead to interindividual differences in these error processing correlates. One hundred sixty participants completed a version of the Eriksen Flanker Task while a 26-channel EEG was recorded. The task was slightly modified in order to increase error rates. During data analysis, participants were split into two groups depending on their DAT1 and their DRD4 genotypes, respectively. ERN and Pe amplitudes after correct responses and after errors as well as difference amplitudes between errors and correct responses were analyzed. We found a differential effect of DAT1 genotype on the Pe difference amplitude but not on the ERN difference amplitude, while the reverse was true for DRD4 genotype. These findings are in line with predictions from theoretical models of dopaminergic transmission in the brain. They furthermore tie results from clinical investigations of disorders impacting on the dopamine system to genetic variations known to be at-risk genotypes. KW - haplotypes KW - electroencephalography KW - basal ganglia KW - reaction time KW - dopaminergics KW - dopamine KW - ADHD KW - research errors Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137930 VL - 6 IS - 12 ER - TY - JOUR A1 - Biehl, Stefanie C. A1 - Merz, Christian J. A1 - Dresler, Thomas A1 - Heupel, Julia A1 - Reichert, Susanne A1 - Jacob, Christian P. A1 - Deckert, Jürgen A1 - Herrmann, Martin J. T1 - Increase or Decrease of fMRI Activity in Adult Attention Deficit/ Hyperactivity Disorder: Does It Depend on Task Difficulty? JF - International Journal of Neuropsychopharmacology N2 - Background: Attention deficit/hyperactivity disorder has been shown to affect working memory, and fMRI studies in children and adolescents with attention deficit/hyperactivity disorder report hypoactivation in task-related attentional networks. However, studies with adult attention deficit/hyperactivity disorder patients addressing this issue as well as the effects of clinically valid methylphenidate treatment are scarce. This study contributes to closing this gap. Methods: Thirty-five adult patients were randomized to 6 weeks of double-blind placebo or methylphenidate treatment. Patients completed an fMRI n-back working memory task both before and after the assigned treatment, and matched healthy controls were tested and compared to the untreated patients. Results: There were no whole-brain differences between any of the groups. However, when specified regions of interest were investigated, the patient group showed enhanced BOLD responses in dorsal and ventral areas before treatment. This increase was correlated with performance across all participants and with attention deficit/hyperactivity disorder symptoms in the patient group. Furthermore, we found an effect of treatment in the right superior frontal gyrus, with methylphenidate-treated patients exhibiting increased activation, which was absent in the placebo-treated patients. Conclusions: Our results indicate distinct activation differences between untreated adult attention deficit/hyperactivity disorder patients and matched healthy controls during a working memory task. These differences might reflect compensatory efforts by the patients, who are performing at the same level as the healthy controls. We furthermore found a positive effect of methylphenidate on the activation of a frontal region of interest. These observations contribute to a more thorough understanding of adult attention deficit/hyperactivity disorder and provide impulses for the evaluation of therapy-related changes. KW - working memory KW - clinical trial KW - child memory KW - short-term methylphenidate brain KW - methylphenidate KW - adult attention deficit/hyperactivity disorder KW - fMRI KW - functional magnetic resonance imaging Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-147551 VL - 19 IS - 10 ER - TY - JOUR A1 - Briegel, Wolfgang T1 - Psychiatric comorbidities in 1p36 deletion syndrome and their treatment — a case report JF - International Journal of Environmental Research and Public Health N2 - 1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap, this case report presents an initially four-year-old girl with 1p36.33–1p36.32 deletion, moderate intellectual disability, insomnia, oppositional-defiant disorder and attention deficit/hyperactivity disorder covering a period of time of about 1.5 years comprising initial psychological/psychiatric assessment, subsequent day clinic/outpatient treatment (amongst others including off-label use of melatonin and methylphenidate as well as parent-child interaction therapy) and follow-up assessment. Follow-up results indicated good efficacy of melatonin and methylphenidate medication without any adverse effects. Multidisciplinarity in diagnosis and treatment are mandatory to meet needs of patients with complex genetic disorders like 1p36 deletion syndrome. Off-label use of melatonin (for insomnia) and methylphenidate (for attention deficit/hyperactivity disorder) should be considered in young children with 1p36 deletion syndrome if behavioral interventions are not sufficient. KW - 1p36 deletion syndrome KW - oppositional-defiant disorder KW - attention deficit/hyperactivity disorder KW - parent-child interaction therapy (PCIT) KW - melatonin KW - methylphenidate KW - off label use KW - case report Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-250189 SN - 1660-4601 VL - 18 IS - 22 ER - TY - JOUR A1 - Briegel, Wolfgang A1 - Andritschky, Christoph T1 - Psychological adjustment of children and adolescents with 22q11.2 deletion syndrome and their mothers' stress and coping — a longitudinal study JF - International Journal of Environmental Research and Public Health N2 - At present, there is a lack of longitudinal studies on the psychological adjustment of both children and adolescents with 22q11.2 deletion syndrome (22q11.2DS) and their primary caregivers. To fill this gap, we performed a four-year follow-up study. Mothers filled out the Child Behavior Checklist 4–18, the Social Orientation of Parents with Handicapped Children questionnaire to assess maternal stress and coping strategies, and the Freiburger Personality Inventory-Revised — subscales strain and life satisfaction. Fifty-five subjects with 22q11.2DS (26 males and 29 females; age: M = 10.79 years, SD = 3.56 years) and their biological mothers (age: M = 40.84 years, SD = 4.68 years) were included in this study. Significantly higher levels of behavior problems than in the general population and an increase in these problems, especially internalizing ones, over time could be found. In contrast, maternal stress did not change significantly over time, but mothers demonstrated increased levels of strain and reduced life satisfaction at T2. Thus, careful monitoring as well as early and adequate interventions, if indicated, should be offered to families with a child with 22q11.2DS, not only for somatic complaints but also for problems with psychological adjustment. KW - 22q11.2 deletion syndrome KW - behavior problems KW - coping strategies KW - longitudinal study KW - maternal stress KW - satisfaction with life Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234101 SN - 1660-4601 VL - 18 IS - 5 ER - TY - JOUR A1 - Briegel, Wolfgang A1 - Greuel, Jan A1 - Stroth, Sanna A1 - Heinrichs, Nina T1 - Parents' perception of their 2−10-year-old children's contribution to the dyadic parent-child relationship in terms of positive and negative behaviors JF - International Journal of Environmental Research and Public Health N2 - Parent-child relationship is developed and changed through reciprocal interactions between a child and his/her parent, and these interactions can strongly influence the child's development across domains (e.g., emotional, physical, and intellectual). However, little is known about the parental perception of the child's contribution to the dyadic parent-child relationship in terms of positive and negative behaviors. We therefore aimed to develop and validate an economical parent-report instrument to assess these important aspects. The validation study included 1642 mothers (M\(_{age}\) = 37.1) and 1068 fathers (M\(_{age}\) = 40.4) of 1712 children aged 2–10 years (M\(_{age}\) = 6.6) who completed the new instrument, the Child Relationship Behavior Inventory (CRBI). Statistical results indicated that the CRBI is a reliable and valid measure. Mothers reported more positive child behaviors towards them, whereas fathers perceived fewer problems with problematic relationship behavior than mothers. In their parents' perception, girls showed more positive and less problematic relationship behaviors than boys. The frequency of problematic child relationship behavior significantly decreased with increasing child age while positive relationship behavior did not show any correlation with the child's age. To assess both positive and negative child relationship behaviors could be helpful to better understand the relevance of these different aspects for the development of the parent-child relationship. KW - parent-child relationship KW - child behavior KW - parental perception KW - inventory Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-197411 SN - 1660-4601 VL - 16 IS - 7 ER - TY - JOUR A1 - Briegel, Wolfgang A1 - Hoyer, Juliane T1 - Psychiatric disorders and distal 21q deletion — a case report JF - International Journal of Environmental Research and Public Health N2 - Partial deletion of chromosome 21q is a very rare genetic condition with highly variable phenotypic features including heart defects, high or cleft palate, brain malformations (e.g., cerebral atrophy), developmental delay and intellectual disability. So far, there is very limited knowledge about psychiatric disorders and their effective treatment in this special population. To fill this gap, the authors present the case of an initially five-year-old girl with distal deletion (del21q22.2) and comorbid oppositional defiant disorder (main psychiatric diagnosis) covering a period of time of almost four years comprising initial psychological/psychiatric assessment, subsequent treatment with Parent–Child Interaction Therapy (PCIT), and follow-up assessments. Post-intervention results including a 19-month follow-up indicated good overall efficacy of PCIT and high parental satisfaction with the treatment. This case report makes a substantial contribution to enhancing knowledge on psychiatric comorbidity and its effective treatment in patients with terminal 21q deletion. Moreover, it emphasizes the necessity of multidisciplinarity in diagnosis and treatment due to the variety of anomalies associated with 21q deletion. Regular screenings for psychiatric disorders and (if indicated) thorough psychological and psychiatric assessment seem to be reasonable in most affected children, as children with developmental delays are at increased risk of developing psychiatric disorders. As demonstrated with this case report, PCIT seems to be a good choice to effectively reduce disruptive behaviors in young children with partial deletion of chromosome 21q. KW - chromosome 21 KW - distal deletion KW - 21q22.2-q22.3 KW - oppositional defiant disorder KW - attention deficit/hyperactivity disorder KW - Parent–Child Interaction Therapy (PCIT) KW - case report Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-203769 SN - 1660-4601 VL - 17 IS - 9 ER - TY - THES A1 - Buchner, Kim T1 - Untersuchungen zur Assoziation von Schlafbruxismus und psychischer Belastung bei Kindern T1 - Studies on the association of sleep bruxism and psychological distress in children N2 - Bruxismus bezeichnet eine sich wiederholende Kaumuskelaktivität mit Knirschen oder Aufeinanderpressen der Zähne. Während bei Erwachsenen die Ursachen und die Pathophysiologie schon weitreichend erforscht wurden, gab es bei Kindern bislang keine systematische Untersuchung hinsichtlich des Zusammenhangs mit psychopathologischen Faktoren. Deshalb wurde unsere Studie nun erstmals mit Bruxismusmessung nach Goldstandard sowie mit normierten und validierten Fragebögen zu verschiedenen psychosozialen Dimensionen als Querschnittsuntersuchung bei 53 acht- bis zwölfjährigen Kindern durchgeführt. Besonderes Augenmerk wurde dabei auf den hypothetisierten Zusammenhang zwischen Schlafbruxismus und Angstsensitivität sowie Angstintensität gelegt. Außerdem wurde der Einfluss weiterer psychosozialer Faktoren (wie Lebensqualität, Anzahl negativer Lebensereignisse, Verhaltensauffälligkeiten, ADHS-Symptomatik, depressive Symptomatik, Zwangssymptomatik, Ticsymptomatik, Alter und Geschlecht) auf die o.g. Prädiktoren per multipler Regressionsanalyse geprüft. Auf Basis der durchgeführten Untersuchung ergaben sich keine Hinweise auf eine Assoziation von Bruxismus zu psychosozialen Dimensionen. Die vorbeschriebenen Zusammenhänge erwiesen sich als statistisch nicht signifikant. Dies mag zum einen der Stichprobenauswahl von gesunden Kindern geschuldet sein, die weder von Bruxismus noch von anderen Faktoren vorbekannt klinisch beeinträchtigt waren. Andererseits können aber auch fehlerhafte Ausgangsüberlegungen durch nicht dem Goldstandard entsprechenden Messungen der Vorstudien zu diesem Ergebnis geführt haben. Darüber hinaus verläuft die Kindesentwicklung interindividuell sehr variabel und temporäre myofunktionelle Beeinträchtigungen können ohne Bezug zu psychischer Belastung auftreten. N2 - Bruxism is defined as repetitive masticatory muscle activity with grinding or clenching of the teeth. While the causes and pathophysiology of bruxism have been extensively studied in adults, there has been no systematic investigation of its association with psychopathological factors in children. Therefore, our study was conducted for the first time with bruxism measurement according to the gold standard as well as with standardized and validated questionnaires on different psychosocial dimensions as a cross-sectional study in 53 eight- to twelve-year-old children. Special attention was paid to the hypothesized relationship between sleep bruxism and anxiety sensitivity as well as anxiety intensity. In addition, the influence of other psychosocial factors (such as quality of life, number of negative life events, behavioral problems, ADHD symptomatology, depressive symptomatology, obsessive-compulsive symptomatology, tic symptomatology, age and gender) on the above predictors was tested by multiple regression analysis. On the basis of the investigation conducted, no evidence of an association of bruxism with psychosocial dimensions was found. The aforementioned associations proved not to be statistically significant. On the one hand, this may be due to the sample selection of healthy children who were not clinically impaired by bruxism or by any other factors known beforehand. On the other hand, faulty initial considerations due to non-gold standard measurements of the preliminary studies may have led to this result. Furthermore, child development is highly variable between individuals and temporary myofunctional impairments may occur without relation to psychological distress. KW - Bruxismus KW - Schlafbruxismus KW - psychische Belastung KW - kindliche Zahnentwicklung KW - Angstsensitivität KW - Angstintensität KW - sleep bruxism KW - psychological distress KW - dental development in children KW - anxiety sensitivity KW - anxiety intensity Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225639 ER - TY - JOUR A1 - Buerger, Arne A1 - Emser, Theresa A1 - Seidel, Alexandra A1 - Scheiner, Christin A1 - von Schoenfeld, Cornelia A1 - Ruecker, Viktoria A1 - Heuschmann, Peter U. A1 - Romanos, Marcel T1 - DUDE - a universal prevention program for non-suicidal self-injurious behavior in adolescence based on effective emotion regulation: study protocol of a cluster-randomized controlled trial JF - Trials N2 - Background Non-suicidal self-injury (NSSI) has become a substantial public health problem. NSSI is a high-risk marker for the development and persistence of mental health problems, shows high rates of morbidity and mortality, and causes substantial health care costs. Thus, there is an urgent need for action to develop universal prevention programs for NSSI before adolescents begin to show this dangerous behavior. Currently, however, universal prevention programs are lacking. Methods The main objective of the present study is to evaluate a newly developed universal prevention program (“DUDE – Du und deine Emotionen / You and your emotions”), based on a skills-based approach in schools, in 3200 young adolescents (age 11–14 years). The effectiveness of DUDE will be investigated in a cluster-randomized controlled trial (RCT) in schools (N = 16). All groups will receive a minimal intervention called “Stress-free through the school day” as a mental health literacy program to prevent burnout in school. The treatment group (N = 1600; 8 schools) will additionally undergo the universal prevention program DUDE and will be divided into treatment group 1 (DUDE conducted by trained clinical psychologists; N = 800; 4 schools) and treatment group 2 (DUDE conducted by trained teachers; N = 800; 4 schools). The active control group (N = 1600; 8 schools) will only receive the mental health literacy prevention. Besides baseline assessment (T0), measurements will occur at the end of the treatment (T1) and at 6- (T2) and 12-month (T3) follow-up evaluations. The main outcome is the occurrence of NSSI within the last 6 months assessed by a short version of the Deliberate Self-Harm Inventory (DSHI-9) at the 1-year follow-up (primary endpoint; T3). Secondary outcomes are emotion regulation, suicidality, health-related quality of life, self-esteem, and comorbid psychopathology and willingness to change. Discussion DUDE is tailored to diminish the incidence of NSSI and to prevent its possible long-term consequences (e.g., suicidality) in adolescents. It is easy to access in the school environment. Furthermore, DUDE is a comprehensive approach to improve mental health via improved emotion regulation. KW - universal prevention KW - NSSI KW - self-injury KW - emotion regulation KW - RCT KW - school-based prevention KW - adolescence Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265874 VL - 23 ER - TY - JOUR A1 - Buerger, Arne A1 - Vloet, Timo D. A1 - Haber, Lisa A1 - Geissler, Julia M. T1 - Third-wave interventions for eating disorders in adolescence - systematic review with meta-analysis JF - Borderline Personality Disorder and Emotion Dysregulation N2 - Context: Third-wave therapies have demonstrated efficacy as a treatment option for EDs in adulthood. Data on the suitability for EDs in adolescence are lacking. Objective: To estimate the efficacy of third-wave interventions to reduce ED symptoms in adolescents in randomized controlled trials (RCTs) and uncontrolled studies. Data sources: We systematically reviewed the databases PubMed (1976-January 2021), PsycINFO (1943-January 2021), and the Cochrane database (1995-January 2021) for English-language articles on third-wave therapies. References were screened for further publications of interest. Study selection: RCTs and pre-post studies without control group, comprising patients aged 11-21 years (mean age = 15.6 years) with an ED diagnosis (anorexia nervosa, bulimia nervosa, binge eating disorder, eating disorder not otherwise specified) investigating the efficacy of third-wave psychological interventions were included. Efficacy had to be evaluated according to the Eating Disorder Examination or Eating Disorder Examination-Questionnaire, the Eating Disorder Inventory-2, the Eating Disorder Inventory-3, or the Structured Interview for Anorexic and Bulimic Disorders for DSM-IV and ICD-10. The outcome assessed in the meta-analysis was the EDE total score. Data extraction: Independent extraction of data by two authors according to a pre-specified data extraction sheet and quality indicators. Data synthesis: We identified 1000 studies after removal of duplicates, assessed the full texts of 48 articles for eligibility, and included 12 studies with a total of 487 participants (female 97.3%/male 2.6%) in the qualitative synthesis and seven studies in the meta-analysis. Articles predominantly reported uncontrolled pre-post trials of low quality, with only two published RCTs. Treatments focused strongly on dialectical behaviour therapy (n = 11). We found moderate effects of third-wave therapies on EDE total score interview/questionnaire for all EDs (d = - 0.67; z = - 5.53; CI95% = - 0.83 to - 0.59). Descriptively, the effects appeared to be stronger in patients with BN and BED. Conclusion: At this stage, it is not feasible to draw conclusions regarding the efficacy of third-wave interventions for the treatment of EDs in adolescence due to the low quality of the empirical evidence. Since almost all of the identified studies used DBT, it is unfortunately not possible to assess other third-wave treatments' efficacy. KW - DBT KW - adolescence KW - eating disorders KW - third-wave psychotherapy KW - meta-analysis KW - review Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-260545 VL - 8 ER - TY - JOUR A1 - Bürger, Arne A1 - Schoenfeld, Cornelia von A1 - Scheiner, Christin A1 - Seidel, Alexandra A1 - Wasserscheid, Antonia A1 - Gad, Doreya A1 - Kittel-Schneider, Sarah A1 - Romanos, Marcel A1 - Reiter, Andrea M. F. T1 - Universal prevention for non-suicidal self-injury in adolescents is scarce - A systematic review JF - Frontiers in Psychiatry N2 - Non-suicidal self-injury (NSSI) during adolescence is a high-risk marker for the development and persistence of mental health problems and has been recognized as a significant public health problem. Whereas targeted prevention has indeed shown to be effective in reducing NSSI and improve mental health problems, access to such programs is limited. By face validity, universal prevention of NSSI seems an ideal starting point for a stepped-care model to circumvent a lack of resources in the medical care system. However, it is yet unclear how effective such approaches are. Here, we provide a summary of existing work on universal prevention of NSSI in adolescents younger than 21 years based on a systematic literature search. We found that only seven studies are available. None of the programs evaluated was found to be effective in reducing the incidence or frequency of NSSI. After providing a comprehensive summary of the existing work, we evaluate the fact that existing work primarily focusses on selected/targeted prevention and on psychoeducational methods. We derive implications for future directions in the field of universal prevention of NSSI. KW - non-suicidal self-injury KW - NSSI KW - emotion regulation KW - prevention KW - universal prevention KW - adolescence KW - mental health Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357490 VL - 14 ER - TY - THES A1 - Calame, Silke T1 - Zusammenhang von Angst mit dem Schweregrad der Anorexia nervosa - Komorbidität am Beispiel einer klinischen Studie T1 - The correlation of anxiety and the degree of anorexia nervosa - comorbidity in an examplary clinical trial N2 - In der Literatur wird eine hohe Komorbidität zwischen Anorexia nervosa und Angststörungen beschrieben. Die Dissertation beinhaltet eine klinische Studie anhand von 29 anorektischen Patientinnen, in der der Zusammenhang zwischen der Ausprägung der Angst und dem Schweregrad der Anorexia nervosa untersucht wurde. Als Testverfahren kamen zur Anwendung State-Trait-Angstinventar (Stai), Sozialphobie und -angstinventar für Kinder (SPAIK), Anorexia nervosa Inventar zur Selbstbeobachtung (ANIS), Fragebogen zum Eßverhalten (FEV), Eating Disorder Inventory (EDI) und Body Mass Index (BMI). Es zeigte sich eine deutliche Korrelation zwischen der Angst und der Ausprägung der psychopathologischen Symptomatik der Eßstörung. Ein vermuteter Zusammenhang zwischen niedrigem Ausgangs - BMI und hohem Angstniveau konnte nicht bestätigt werden. N2 - In literature a high comorbidity between anxiety disorders and anorexia nervosa is being described. The dissertation contains a clinical study on 29 female anorectic patients investigating the correlation between the level of anxiety and the degree of anorxia nervosa. As methods have been used Eating-Disorder-Inventory (EDI), Three-Factor Eating Questionnaire (FEV), Anorexia Nervosa Inventory of Self-Rating (ANIS), Social Phobia and Anxiety Inventory for Children (SPAI-C), State-Trait Anxiety Inventory (STAI) and body mass index (BMI). A correlation between anxiety and degree of psychopsychological symptoms of the eating disorder was seen. Surprisingly no connection between starting BMI and high anxiety level was found. KW - Anorexia nervosa KW - Angst KW - Komorbidität KW - Angststörungen KW - Eßstörungen KW - anorexia nervosa KW - anxiety KW - comorbidity KW - anxiety disorders KW - eating disorders Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-13830 ER - TY - JOUR A1 - Capetian, Philipp A1 - Roessner, Veit A1 - Korte, Caroline A1 - Walitza, Susanne A1 - Riederer, Franz A1 - Taurines, Regina A1 - Gerlach, Manfred A1 - Moser, Andreas T1 - Altered urinary tetrahydroisoquinoline derivatives in patients with Tourette syndrome: reflection of dopaminergic hyperactivity? JF - Journal of Neural Transmission N2 - Tetrahydroisoquinolines (TIQs) such as salsolinol (SAL), norsalsolinol (NSAL) and their methylated derivatives N-methyl-norsalsolinol (NMNSAL) and N-methyl-salsolinol (NMSAL), modulate dopaminergic neurotransmission and metabolism in the central nervous system. Dopaminergic neurotransmission is thought to play an important role in the pathophysiology of chronic tic disorders, such as Tourette syndrome (TS). Therefore, the urinary concentrations of these TIQ derivatives were measured in patients with TS and patients with comorbid attention-deficit/hyperactivity disorder (TS + ADHD) compared with controls. Seventeen patients with TS, 12 with TS and ADHD, and 19 age-matched healthy controls with no medication took part in this study. Free levels of NSAL, NMNSAL, SAL, and NMSAL in urine were measured by a two-phase chromatographic approach. Furthermore, individual TIQ concentrations in TS patients were used in receiver-operating characteristics (ROC) curve analysis to examine the diagnostic value. NSAL concentrations were elevated significantly in TS [434.67 ± 55.4 nmol/l (standard error of mean = S.E.M.), two-way ANOVA, p < 0.0001] and TS + ADHD patients [605.18 ± 170.21 nmol/l (S.E.M.), two-way ANOVA, p < 0.0001] compared with controls [107.02 ± 33.18 nmol/l (S.E.M.), two-way ANOVA, p < 0.0001] and NSAL levels in TS + ADHD patients were elevated significantly in comparison with TS patients (two-way ANOVA, p = 0.017). NSAL demonstrated an AUC of 0.93 ± 0.046 (S.E.M) the highest diagnostic value of all metabolites for the diagnosis of TS. Our results suggest a dopaminergic hyperactivity underlying the pathophysiology of TS and ADHD. In addition, NSAL concentrations in urine may be a potential diagnostic biomarker of TS. KW - Tourette syndrome KW - ADHD KW - tics KW - biomarkers KW - tetrahydroisoquinoline derivates Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-235771 SN - 0300-9564 VL - 128 ER - TY - THES A1 - Carl, Sophia Leonie T1 - Untersuchungen zum Einfluss serotonerger Genvariationen auf olfaktorische Performanz T1 - Investigations on the influence of serotonergic gene polymorphisms on olfactory performance N2 - Einige psychiatrische Erkrankungen gehen mit einer Veränderung der Riechfunktion einher. In aktuellen Tiermodellen wurde durch Stimulation der Raphe Kerne, die unter anderem zum Bulbus Olfaktorius projizieren, das serotonerge System als Einflussfaktor der Riechfunktion erkannt. Unsere Hypothese geht davon aus, dass das serotonerge System die Riechleistung beeinflussen könnte. Um diese Hypothese zu überprüfen, wurden drei Gene des serotonergen Systems und deren psychiatrisch relevante Genpolymorphismen ausgewählt und untersucht: TPH2 (Tryptophanhydroxylase 2, rs4570625), 5-HTTLPR (Serotonintransporter-Längenpolymorphismus) und 5-HT2C (Serotonintransporter, rs3813929). Insgesamt wurden 173 gesunde Kinder eingeschlossen und auf deren Riechleistung (Riechschwelle und Diskrimination) hin mittels des Sniffin’Sticks Tests untersucht. Träger des T-Allels des TPH2-Polymorphismus sowie Träger des s-Allels, des 5-HTTLPR wiesen eine signifikant bessere Diskrimination von Gerüchen auf. Der Effekt des 5-HTTLPR ließ sich auf die Mädchen in der Stichprobe zurückführen. Der Genpolymorphismus des 5-HT2C Rezeptors wirkte sich nicht signifikant auf die Riechleistung aus. In Bezug auf die Riechsensitivität zeigten sich keine signifikanten Modulationen durch die untersuchten Genvarianten. Gene des serotonergen Systems üben bei gesunden Kindern einen modulierenden Einfluss auf die Riechfunktion aus, insbesondere auf die Riechdiskrimination. Von besonderer Bedeutung scheinen in diesem Zusammenhang der Serotonintransporter 5-HTTLPR und das Syntheseenzym TPH2 zu sein. N2 - Some psychiatric disorders are associated with a modulation of the olfactory system. By stimulating the raphe nuclei, which among other target regions project to the olfactory bulb, the serotonergic system was recognized as an influencing factor of the olfactory function in current animal models. Our hypothesis assumes that the serotonergic system influences the olfactory performance. To test this hypothesis, three genes of the serotoninergic system and their psychollogical relevant gene polymorphisms were selected and investigated: TPH2 (tryptophan hydroxylase 2, rs4570625), 5-HTT LPR (serotonin transporter length polymorphism) and 5-HT2C (serotonin transporter, rs3813929). A total of 173 healthy children were included and examined for their olfactory performance (olfactory threshold and discrimination) using the Sniffin'Sticks test. Carriers of the T-allele of the TPH2 polymorphism as well as carriers of the s-allele of the 5-HTTLPR, exhibited significantly better odor discrimination. The effect of 5-HTTLPR polymorphism was mediated by the girls in the sample. The gene polymorphism of the 5-HT2C receptor did not significantly affect the olfactory function. In terms of odor sensitivity, no significant modulations were mediated by the examined gene variants. Genes of the serotonergic system exert a modulating influence on the olfactory function in healthy children, especially on olfactory discrimination. Of particular importance in this context are the serotonin transporter 5-HTT LPR and the synthesis enzyme TPH2. KW - Riechen KW - Diskrimination KW - Serotonin KW - Serotonerges System KW - Genpolymophismen KW - Olfaction KW - Discrimination Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-185418 ER - TY - THES A1 - Claus, Armin T1 - Wirksamkeit und Verträglichkeit des Dopamin-Agonisten Ropinirol bei jungen Patienten mit hyperkinetischer Störung T1 - Efficacy and safety of the dopamine agonist ropinirole in the treatment of boys with attention deficit hyperactivity disorder N2 - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) ist eine häufige Erkran-kung bei Kindern und Jugendlichen. Vor allem bei Ausbleiben einer suffizienten Be-handlung verursacht die ADHS sehr oft vielfältige Probleme, die das Leben der Be-troffenen in Familie, Schule und Freizeit gravierend beeinträchtigen. Zahlreiche Studien beschreiben eine Dysfunktion des dopaminergen Systems als Hauptursache für das Auf-treten der Kardinalsymptome Hyperaktivität, Konzentrationsmangel und Impulsivität. Die Hauptsäule der medikamentösen Behandlung ist das zwingend per Betäubungsmit-telrezept zu verordnende Stimulanz METHYLPHENIDAT mit eigenem Nebenwir-kungsprofil und einer nicht geringen Rate an Nonrespondern. Einzelne Literaturstellen und theoretische Vorüberlegungen lassen eine Korrektur dys-funktionaler dopaminerger Transmitterprozesse bei ADHS nicht allein durch Stimulanzi-en, sondern auch durch die Klasse der Dopamin-Agonisten denkbar erscheinen. Diese Vorüberlegungen basieren u. a. auf den Kenntnissen der Eigenschaften und des Wirkmechanismus des Dopamin-Agonisten ROPINIROL, der vielfach in der Behandlung der Parkinson-Krankheit eingesetzt wird. Dieser Heilversuch ist die erste prospektive Untersuchung zur Sicherheit und Wirksam-keit des Dopamin-Agonisten ROPINIROL in der Behandlung von jungen männlichen ADHS-Patienten. Gleichzeitig liegt damit auch der erste Wirksamkeitsvergleich des erstmals gezielt zur ADHS-Behandlung eingesetzten Wirkstoffes ROPINIROL mit der Goldstandard-Substanz der ADHS-Medikation, nämlich METHYLPHENIDAT vor. Insgesamt nahmen 9 Jungen mit ADHS im Alter zwischen 8 und 13 Jahren an dem Heilversuch teil, 3 dieser 9 Probanden im Rahmen eines Vortests, die übrigen 6 unter den Bedingungen des endgültigen Heilversuchs. Die Effekte der jeweils eingesetzten Substanz auf die Symptomausprägung der ADHS wurden mit Hilfe der Kurzform des Eltern-Lehrer-Fragebogens nach Conners und speziell hinsichtlich der ADHS-relevanten Verhaltensparameter Konzentrationsfähigkeit und Impulskontrolle durch den computer-gestützten Continuous Performance Test, CPT, erhoben. Im Bild der angewandten computergestützten Konzentrations- und Impulskontroll-belastungstests (CPT) ergab sich bei 2 der 6 Probanden des Hauptheilversuches unter ROPINIROL eine sehr deutliche Verbesserung der Konzentration (Steigerung der rich-tigen Tastendrücke um 30% bzw. 70%). In der Betrachtung der gesamten Probanden-gruppe war der die Konzentration fördernde Effekt von ROPINIROL aber unspezifisch (p=0,463) und blieb weit hinter dem statistisch signifikanten konzentrationsfördernden Effekt von METHYLPHENIDAT auf die Probandengruppe (p=0,021) zurück. 5 von 6 Probanden handelten unter ROPINIROL weniger impulsiv und reduzierten die Anzahl falscher Tastendrücke im CPT gering bis deutlich. 3 dieser 5 Probanden verrin-gerten diese Fehlerzahl unter ROPINIROL um mindestens 40% der Ausgangsfehlerzahl ohne Medikation. Anders als beim Verhaltensparameter Konzentration ließ sich hinsichtlich der Impuls-kontrolle kein Nachteil der Medikation mit ROPINIROL gegenüber METHYLPHENI-DAT errechnen. Auch in der Auswertung der Kurzform des Eltern-Lehrer-Fragebogens nach Conners war ROPINIROL METHYLPHENIDAT rechnerisch nicht signifikant unterlegen. We-gen der kleinen Probandengruppe in Verbindung mit der deutlichen Streubreite der Er-gebnisse zur Impulsivität und innerhalb der Conners-Skalen kann dies aber bestenfalls als Hinweis, nicht aber als rechnerisch bewiesene Ähnlichkeit der Wirkstärke beider Substanzen in der Verbesserung vor allem der Impulskontrolle interpretiert werden. 6 von 9 Probanden beschrieben unter Ropinirol spürbare Tagesmüdigkeit. Diese war unter den höheren Dosen Ropinirol des Vortestes (max. 2mg ROP/die) besonders häufig und stark (3 von 3 Probanden). Unter der reduzierten Enddosis von maximal 1mg ROP/die im Haupttest lag die Häufigkeit der Tagesmüdigkeit bei 4 von 6 Probanden und wurde weniger stark erlebt. Dies weist auf eine Dosisabhängigkeit dieser im Heil-versuch am häufigsten registrierten unerwünschten Wirkung von Ropinirol hin. Impera-tive Schlafattacken blieben vollständig aus. Der Beweis für das Potential des Dopamin-Agonisten ROPINIROL, die Symptome einer ADHS in ähnlichem Ausmaß wie das Stimulanz METHYLPHENIDAT zu verrin-gern oder zumindest statistisch fassbar zu reduzieren, konnte in der Gesamtwürdigung der Ergebnisse dieses Heilversuchs nicht erbracht werden. Es ergaben sich aber einzelne Hinweise auf eine Teilwirksamkeit von ROPINIROL gegen ADHS-Symptome bei einzelnen Probanden, vor allem für den Symptombereich der Impulsivi-tät. Hinweise auf ein Nebenwirkungsprofil, das jede zukünftige Anwendung von ROPINIROL bei ADHS-Erkrankten ausschließt, wurden nicht festgestellt. Die mit Hilfe dieses pilotstudienartigen Heilversuchs gewonnenen Erkenntnisse könnten durch breiter angelegte Studien z. B. im Design einer randomisierten doppelblinden Wirksamkeitsvergleichsstudie überprüft und weiterentwickelt werden, um die mögliche Eignung von Dopamin-Agonisten wie Ropinirol als medikamentöse Alternative für be-stimmte Subpopulationen von ADHS-Betroffenen besser beurteilen zu können. N2 - Efficacy and safety of the dopamine agonist ropinirole in the treatment of boys with attention deficit hyperactivity disorder KW - Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung KW - attention deficit hyperactivity disorder KW - ADHS KW - Ropinirol KW - Dopamin Agonist KW - Methylphenidat KW - Stimulanz KW - Medikation KW - Behandlung KW - ADHD KW - ropinirole KW - dopamine agonist KW - methylphenidate KW - stimulant KW - medication KW - treatment Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-103065 ER - TY - THES A1 - Daub, Jonas T1 - Der Einfluss von Alter und Ängstlichkeit auf die Furchtgeneralisierung und die Aufmerksamkeitslenkung bei gesunden Kindern und Jugendlichen T1 - The influence of age and anxiety on fear generalization and attentional processes in healthy children and adolescents N2 - Mittels einer klinischen Studie wurden die Furchtgeneralisierung und Aufmerksamkeitslenkung von 44 gesunden Kindern und Jugendlichen im Alter von 9-17 Jahren untersucht. Eine Übergeneralisierung konditionierter Furcht sowie veränderte Aufmerksamkeitsprozesse werden in zahlreichen Arbeiten mit der Entstehung und Aufrechterhaltung von Angsterkrankungen in Verbindung gebracht. Der Hauptteil der Forschung beschränkte sich bislang auf die Untersuchung von erwachsenen Probanden. Da Angsterkrankungen jedoch häufig bereits im Kindes- und Jugendalter entstehen und sich in der Erforschung psychiatrischer Erkrankungen zunehmend eine dimensionale Betrachtungsweise durchsetzt, bestand das Ziel der Studie darin, etwaige Alterseffekte und den Einfluss der Ängstlichkeit auf die genannten Phänomene bei gesunden Probanden zu untersuchen. Darüber hinaus wurde ein potentiell präventiver Ansatz erforscht. Im Ergebnis zeigten sich in den Gruppenvergleichen keine relevanten Differenzen. Interessanterweise deutete sich in der Gruppe der älteren Probanden entgegen der Erwartung eine verstärkte Furchtgeneralisierung an, die womöglich mit einer veränderten Beziehung zu Furcht und Risiko in der Adoleszenz zusammenhängt. Aus den Befunden ergibt sich die Notwendigkeit weiterer, prospektiver Arbeiten, um unser Verständnis der Ätiologie von Angsterkrankungen zu verbessern. Weiterhin ist noch offen, inwiefern es sich bei der Übergeneralisierung und einer veränderten Aufmerksamkeitslenkung um Risikofaktoren für die Entwicklung von Angsterkrankungen oder vielmehr um Epiphänomene handelt, die erst mit Ausbruch der Erkrankung auftreten. Der Einsatz von Methoden der virtuellen Realität erscheint besonders geeignet, diese Prozesse zukünftig noch besser zu erforschen. N2 - In this clinical study fear generalization and attentional processes have been investigated in 44 healthy children and adolescents aged 9-17 years. Overgeneralization of conditioned fear and altered attentional processes have been linked to the development and maintenance of anxiety disorders in numerous studies. The majority of research to date has been limited to the study of adult subjects. However, since anxiety disorders often develop in childhood and adolescence and a dimensional approach has become increasingly important in the study of psychiatric disorders, the aim of the study was to investigate age effects and the influence of anxiety on the aforementioned phenomena in healthy subjects. In addition, a potential preventive approach has been studied. The results showed no relevant differences in the group comparisons. Interestingly and contrary to expectations, there was a trend for increased fear generalization in the group of older subjects, which can possibly be related to a changed relationship to fear and risk in adolescence. The findings suggest the need for further, prospective work to improve our understanding of the aetiology of anxiety disorders. Furthermore, it is still open to what extent overgeneralization and altered attentional processes are risk factors for the development of anxiety disorders or rather epiphenomena that only appear with the onset of the disorder. The use of virtual reality methods seems particularly suitable for researching these processes even better in the future. KW - Angst KW - Furcht KW - Anxiety KW - Fear KW - Klinisches Experiment KW - Furchtgeneralisierung KW - Aufmerksamkeitsprozesse KW - Angsterkrankungen KW - Kinder- und Jugendpsychiatrie KW - klinische Studie KW - fear generalization KW - attentional processes KW - anxiety disorders KW - child and adolescent psychiatry KW - clinical study Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300100 ER - TY - JOUR A1 - Davis, Lea K. A1 - Yu, Dongmei A1 - Keenan, Clare L. A1 - Gamazon, Eric R. A1 - Konkashbaev, Anuar I. A1 - Derks, Eske M. A1 - Neale, Benjamin M. A1 - Yang, Jian A1 - Lee, S. Hong A1 - Evans, Patrick A1 - Barr, Cathy L. A1 - Bellodi, Laura A1 - Benarroch, Fortu A1 - Berrio, Gabriel Bedoya A1 - Bienvenu, Oscar J. A1 - Bloch, Michael H. A1 - Blom, Rianne M. A1 - Bruun, Ruth D. A1 - Budman, Cathy L. A1 - Camarena, Beatriz A1 - Campbell, Desmond A1 - Cappi, Carolina A1 - Cardona Silgado, Julio C. A1 - Cath, Danielle C. A1 - Cavallini, Maria C. A1 - Chavira, Denise A. A1 - Chouinard, Sylvian A1 - Conti, David V. A1 - Cook, Edwin H. A1 - Coric, Vladimir A1 - Cullen, Bernadette A. A1 - Deforce, Dieter A1 - Delorme, Richard A1 - Dion, Yves A1 - Edlund, Christopher K. A1 - Egberts, Karin A1 - Falkai, Peter A1 - Fernandez, Thomas V. A1 - Gallagher, Patience J. A1 - Garrido, Helena A1 - Geller, Daniel A1 - Girard, Simon L. A1 - Grabe, Hans J. A1 - Grados, Marco A. A1 - Greenberg, Benjamin D. A1 - Gross-Tsur, Varda A1 - Haddad, Stephen A1 - Heiman, Gary A. A1 - Hemmings, Sian M. J. A1 - Hounie, Ana G. A1 - Illmann, Cornelia A1 - Jankovic, Joseph A1 - Jenike, Micheal A. A1 - Kennedy, James L. A1 - King, Robert A. A1 - Kremeyer, Barbara A1 - Kurlan, Roger A1 - Lanzagorta, Nuria A1 - Leboyer, Marion A1 - Leckman, James F. A1 - Lennertz, Leonhard A1 - Liu, Chunyu A1 - Lochner, Christine A1 - Lowe, Thomas L. A1 - Macciardi, Fabio A1 - McCracken, James T. A1 - McGrath, Lauren M. A1 - Restrepo, Sandra C. Mesa A1 - Moessner, Rainald A1 - Morgan, Jubel A1 - Muller, Heike A1 - Murphy, Dennis L. A1 - Naarden, Allan L. A1 - Ochoa, William Cornejo A1 - Ophoff, Roel A. A1 - Osiecki, Lisa A1 - Pakstis, Andrew J. A1 - Pato, Michele T. A1 - Pato, Carlos N. A1 - Piacentini, John A1 - Pittenger, Christopher A1 - Pollak, Yehunda A1 - Rauch, Scott L. A1 - Renner, Tobias J. A1 - Reus, Victor I. A1 - Richter, Margaret A. A1 - Riddle, Mark A. A1 - Robertson, Mary M. A1 - Romero, Roxana A1 - Rosàrio, Maria C. A1 - Rosenberg, David A1 - Rouleau, Guy A. A1 - Ruhrmann, Stephan A1 - Ruiz-Linares, Andreas A1 - Sampaio, Aline S. A1 - Samuels, Jack A1 - Sandor, Paul A1 - Sheppard, Broke A1 - Singer, Harvey S. A1 - Smit, Jan H. A1 - Stein, Dan J. A1 - Strengman, E. A1 - Tischfield, Jay A. A1 - Valencia Duarte, Ana V. A1 - Vallada, Homero A1 - Van Nieuwerburgh, Flip A1 - Veenstra-VanderWeele, Jeremy A1 - Walitza, Susanne A1 - Wang, Ying A1 - Wendland, Jens R. A1 - Westenberg, Herman G. M. A1 - Shugart, Yin Yao A1 - Miguel, Euripedes C. A1 - McMahon, William A1 - Wagner, Michael A1 - Nicolini, Humberto A1 - Posthuma, Danielle A1 - Hanna, Gregory L. A1 - Heutink, Peter A1 - Denys, Damiaan A1 - Arnold, Paul D. A1 - Oostra, Ben A. A1 - Nestadt, Gerald A1 - Freimer, Nelson B. A1 - Pauls, David L. A1 - Wray, Naomi R. A1 - Stewart, S. Evelyn A1 - Mathews, Carol A. A1 - Knowles, James A. A1 - Cox, Nancy J. A1 - Scharf, Jeremiah M. T1 - Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture JF - PLoS Genetics N2 - The direct estimation of heritability from genome-wide common variant data as implemented in the program Genome-wide Complex Trait Analysis (GCTA) has provided a means to quantify heritability attributable to all interrogated variants. We have quantified the variance in liability to disease explained by all SNPs for two phenotypically-related neurobehavioral disorders, obsessive-compulsive disorder (OCD) and Tourette Syndrome (TS), using GCTA. Our analysis yielded a heritability point estimate of 0.58 (se = 0.09, p = 5.64e-12) for TS, and 0.37 (se = 0.07, p = 1.5e-07) for OCD. In addition, we conducted multiple genomic partitioning analyses to identify genomic elements that concentrate this heritability. We examined genomic architectures of TS and OCD by chromosome, MAF bin, and functional annotations. In addition, we assessed heritability for early onset and adult onset OCD. Among other notable results, we found that SNPs with a minor allele frequency of less than 5% accounted for 21% of the TS heritability and 0% of the OCD heritability. Additionally, we identified a significant contribution to TS and OCD heritability by variants significantly associated with gene expression in two regions of the brain (parietal cortex and cerebellum) for which we had available expression quantitative trait loci (eQTLs). Finally we analyzed the genetic correlation between TS and OCD, revealing a genetic correlation of 0.41 (se = 0.15, p = 0.002). These results are very close to previous heritability estimates for TS and OCD based on twin and family studies, suggesting that very little, if any, heritability is truly missing (i.e., unassayed) from TS and OCD GWAS studies of common variation. The results also indicate that there is some genetic overlap between these two phenotypically-related neuropsychiatric disorders, but suggest that the two disorders have distinct genetic architectures. KW - TIC disorders KW - missing heritability KW - complex diseases KW - neuropsychiatric disorders KW - common SNPS KW - gilles KW - family KW - brain KW - expression KW - autism Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127377 SN - 1553-7390 VL - 9 IS - 10 ER - TY - JOUR A1 - Dempfle, Astrid A1 - Herpertz-Dahlmann, Beate A1 - Timmesfeld, Nina A1 - Schwarte, Reinhild A1 - Egberts, Karin M. A1 - Pfeiffer, Ernst A1 - Fleischhaker, Christian A1 - Wewetzer, Christoph A1 - Bühren, Katharina T1 - Predictors of the resumption of menses in adolescent anorexia nervosa JF - BMC Psychiatry N2 - Background: The resumption of menses is an important indicator of recovery in anorexia nervosa (AN). Patients with early-onset AN are at particularly great risk of suffering from the long-term physical and psychological consequences of persistent gonadal dysfunction. However, the clinical variables that predict the recovery of menstrual function during weight gain in AN remain poorly understood. The aim of this study was to investigate the impact of several clinical parameters on the resumption of menses in first-onset adolescent AN in a large, well-characterized, homogenous sample that was followed-up for 12 months. Methods: A total of 172 female adolescent patients with first-onset AN according to DSM-IV criteria were recruited for inclusion in a randomized, multi-center, German clinical trial. Menstrual status and clinical variables (i.e., premorbid body mass index (BMI), age at onset, duration of illness, duration of hospital treatment, achievement of target weight at discharge, and BMI) were assessed at the time of admission to or discharge from hospital treatment and at a 12-month follow-up. Based on German reference data, we calculated the percentage of expected body weight (%EBW), BMI percentile, and BMI standard deviation score (BMI-SDS) for all time points to investigate the relationship between different weight measurements and resumption of menses. Results: Forty-seven percent of the patients spontaneously began menstruating during the follow-up period. %EBW at the 12-month follow-up was strongly correlated with the resumption of menses. The absence of menarche before admission, a higher premorbid BMI, discharge below target weight, and a longer duration of hospital treatment were the most relevant prognostic factors for continued amenorrhea. Conclusions: The recovery of menstrual function in adolescent patients with AN should be a major treatment goal to prevent severe long-term physical and psychological sequelae. Patients with premenarchal onset of AN are at particular risk for protracted amenorrhea despite weight rehabilitation. Reaching and maintaining a target weight between the 15th and 20th BMI percentile is favorable for the resumption of menses within 12 months. Whether patients with a higher premorbid BMI may benefit from a higher target weight needs to be investigated in further studies. KW - girls KW - amenorrhea KW - brain KW - increases KW - return KW - menarche KW - target weight KW - adolescence anorexia nervosa KW - resumption of menses KW - recovery KW - ovarian function KW - weight gain KW - eating disorders KW - bone-mineral density KW - menstrual recovery KW - outcome KW - body mass index Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122106 VL - 13 IS - 308 ER - TY - THES A1 - Eckert, Lisa Doreen T1 - Multimodale Verfahren zum Eisenstoffwechsel bei ADHS - Vergleichende Bildgebung T1 - Multimodal methods for iron metabolism in ADHD - Comparative imaging N2 - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) gehört weltweit zu den bedeutendsten psychiatrischen Erkrankungen des Kinder- und Jugendalters. Die Pathomechanismen sind aktuell noch nicht vollständig geklärt, wobei es deutliche Hinweise auf hirnorganische Veränderungen gibt. Die transkranielle Sonographie stellt eine nicht-invasive Methode dar, strukturelle Unterschiede tiefer Hirnstrukturen zu untersuchen. Bereits in vorangegangenen Studien konnte mit der Methode eine Veränderung der Echogenität der Substantia nigra (SN) bei Kindern mit ADHS im Vergleich zu gesunden Kontrollprobanden nachgewiesen werden. In dieser Studie sollen nun die möglichen physiologischen Hintergründe der erhöhten Echogenität der Substantia Nigra in Zusammenschau mit bildgebenden Verfahren betrachtet werden. Hierzu wurde in der vorliegenden multimodalen Studie bei 20 männlichen Kindern mit ADHS im Alter zwischen 8 und 12 Jahren eine transkranielle Ultraschalluntersuchung (TCS) zur Bestimmung der echogenen Fläche der Substantia Nigra sowie ein neuromelaninsensitives cMRT zur Bestimmung des neuromelaninassoziierten Volumens der SN, sowie des neuromelaninassoziierten Kontrastes SN/Cb durchgeführt. Als Kennwerte des peripheren Eisenhaushalts wurden die Konzentrationen von Eisen, Ferritin und Transferrin im Blut bestimmt. In die Auswertung gingen außerdem die Stärke der ADHS-Symptomatik (Strength and Difficulties Questionaire, SDQ; Fremdbeurteilungsbogen bei ADHS, FBB-ADHS), die kognitive Begabung (über CFT-20-R) und das Alter der Probanden ein. Psychiatrische Komorbidität wurde mit Hilfe der Child Behaviour Checklist (CBCL) erhoben. N2 - Attention deficit/hyperactivity disorder (ADHD) is one of the most important psychiatric diseases of children and adolescents worldwide. The pathomechanisms are currently not yet fully understood, although there are clear indications of organic brain changes. Transcranial sonography is a non-invasive method, to investigate structural differences in deep brain structures. In previous studies, the method was able to demonstrate a change in the echogenicity of the substantia nigra (SN) in children with ADHD compared to healthy control subjects. This study investigates the possible physiological background of the increased echogenicity of the substantia nigra including imaging procedures. For this purpose, in the present multimodal study, a transcranial ultrasound examination (TCS) to determine the echogenic area of the substantia nigra and a neuromelanin-sensitive cMRI to detect the neuromelanin-associated volume of the SN and the neuromelanin-associated Contras SN/Cb were used in 20 male children with ADHD between the ages of 8 and 12 years. The concentrations of iron, ferritin and transferrin in the blood were determined as parameters of the peripheral iron balance. The evaluation also included the strength of the ADHD symptoms (Strength and Difficulties Questionnaire, SDQ; external assessment form for ADHD, FBB-ADHD), the cognitive ability (via CFT-20-R) and the age of the test subjects. Psychiatric comorbidity was assessed using the Child Behavior Checklist (CBCL). KW - TCS KW - Neuromelanin KW - ADHS KW - Transkranielle Sonographie KW - Aufmerksamkeitsdefizit-Syndrom KW - Zweikomponentensystem KW - Eisen Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-348295 ER - TY - JOUR A1 - Egberts, Karin A1 - Fekete, Stefanie A1 - Häge, Alexander A1 - Hiemke, Christoph A1 - Scherf-Clavel, Maike A1 - Taurines, Regina A1 - Unterecker, Stefan A1 - Gerlach, Manfred A1 - Romanos, Marcel T1 - Therapeutisches Drug Monitoring zur Optimierung der Psychopharmakotherapie von Kindern und Jugendlichen: Update und Leitfaden für die Praxis JF - Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie N2 - Trotz verbesserter Evidenzbasis bestehen in der kinder- und jugendpsychiatrischen Pharmakotherapie viele Unsicherheiten über die Wirkung und Verträglichkeit der häufig off-label oder in Kombinationstherapie verordneten Medikamente. Gerade auch vor dem Hintergrund der in vielen Fällen notwendigen mittel- bis langfristigen Einnahme sollen unerwünschte Arzneimittelwirkungen in dieser Altersstufe möglichst minimiert und eine auf die individuellen Charakteristika der Patientin oder des Patienten zugeschnittene, effektive Dosierung gefunden werden. Kinder und Jugendliche scheinen nicht nur besonders anfällig für bestimmte unerwünschte Arzneimittelwirkungen, sondern sind auch iatrogenen Risiken durch Dosierungs- oder Applikationsfehler ausgesetzt, die zu Unter- oder Überdosierungen führen können mit entsprechend negativen Auswirkungen auf den Therapieerfolg. Neben einer strengen Indikationsstellung sind daher eine präzise Dosisfindung sowie systematische Überwachung der Sicherheit der Psychopharmakotherapie unverzichtbar. In diesem Artikel wird Therapeutisches Drug Monitoring als hilfreiches klinisches Instrument vorgestellt und beschrieben, wie dessen richtige Anwendung sowohl die Wirksamkeit als auch die Sicherheit und Verträglichkeit einer Psychopharmakotherapie im Kindes- und Jugendalter zum unmittelbaren Nutzen für die Patientinnen und Patienten verbessern kann. N2 - Despite the improved evidence base, many uncertainties remain in child and adolescent psychiatric pharmacotherapy about the efficacy and tolerability of drugs, which are often prescribed off-label or in combination therapy in this age group. Because medium- to long-term use is unavoidable in many cases, clinicians should minimize adverse drug reactions as far as possible and tailor an effective dosage to the individual characteristics of the patient. Not only are children and adolescents particularly vulnerable to certain adverse drug effects, they are also exposed to iatrogenic risks from dosing or application errors, which can lead to under- or overdosing with correspondingly negative effects on the success of the therapy. In addition to determining a strict indication, it is therefore essential to establish precise dosage and systematic monitoring of the safety of the psychopharmacotherapy. This article introduces therapeutic drug monitoring as a useful clinical tool and describes how its correct application in practice can improve the efficacy as well as the safety and tolerability of psychotropic therapy in children and adolescents for the immediate benefit of patients. T2 - Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice KW - Psychopharmakotherapie KW - unerwünschte Arzneimittelwirkungen KW - Pharmakovigilanz KW - Therapeutisches Drug Monitoring KW - Qualitätssicherung KW - psychopharmacotherapy KW - adverse drug reactions KW - pharmacovigilance KW - therapeutic drug monitoring KW - quality assurance Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262038 SN - 1422-4917 SN - 1664-2880 VL - 50 IS - 2 ER - TY - JOUR A1 - Emser, Theresa S. A1 - Johnston, Blair A. A1 - Steele, J. Douglas A1 - Kooij, Sandra A1 - Thorell, Lisa A1 - Christiansen, Hanna T1 - Assessing ADHD symptoms in children and adults: evaluating the role of objective measures JF - Behavioral and Brain Functions N2 - Background: Diagnostic guidelines recommend using a variety of methods to assess and diagnose ADHD. Applying subjective measures always incorporates risks such as informant biases or large differences between ratings obtained from diverse sources. Furthermore, it has been demonstrated that ratings and tests seem to assess somewhat different constructs. The use of objective measures might thus yield valuable information for diagnosing ADHD. This study aims at evaluating the role of objective measures when trying to distinguish between individuals with ADHD and controls. Our sample consisted of children (n = 60) and adults (n = 76) diagnosed with ADHD and matched controls who completed self- and observer ratings as well as objective tasks. Diagnosis was primarily based on clinical interviews. A popular pattern recognition approach, support vector machines, was used to predict the diagnosis. Results: We observed relatively high accuracy of 79% (adults) and 78% (children) applying solely objective measures. Predicting an ADHD diagnosis using both subjective and objective measures exceeded the accuracy of objective measures for both adults (89.5%) and children (86.7%), with the subjective variables proving to be the most relevant. Conclusions: We argue that objective measures are more robust against rater bias and errors inherent in subjective measures and may be more replicable. Considering the high accuracy of objective measures only, we found in our study, we think that they should be incorporated in diagnostic procedures for assessing ADHD. KW - ADHD KW - support vector machines KW - classification KW - objective assessment KW - children/adults Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-175717 VL - 14 IS - 11 ER - TY - THES A1 - Euteneuer, Wolfram T1 - Nierentransplantation an der Universität Würzburg - eine retrospektive Datenanalyse von 1984 bis 2004 T1 - Nephrotransplantation at the University of Würzburg - a retrospective data-analysis from 1984 to 2004 N2 - Am Klinikum der Julius-Maximilians-Universität Würzburg werden seit Dezember 1984 Nierentransplantationen durchgeführt. Die vorliegende Arbeit erfasst retrospektiv den Zeitraum zwischen 1984 und 2004 und versucht, ein Bild von der Entwicklung des Nierentransplantationsprogramms in Würzburg und den erreichten Erfolgen zu vermitteln. Im Laufe dieser Zeit unterlag die Population der Organspender und der Organempfänger einem stetigen Wandel, während sich die eingesetzten immunsuppressiven Schemata häufig veränderten. Viele neue Medikamente wurden im Laufe der Jahre eingeführt und Therapierichtlinien definiert, die zielgenauer das Immunsystem therapeutisch ausschalteten. N2 - This is a retrospective data-analysis of the kidney transplantation program of the university of wuerzburg. From 1984 to 2004 about 560 transplantations were recorded in a data base. KW - Nierentransplantion KW - Transplantation KW - Immunsuppression KW - Transplantatüberleben KW - nephrotransplantation KW - renal KW - transplantation KW - immunosuppression Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-20759 ER - TY - JOUR A1 - Farmer, Adam D. A1 - Strzelczyk, Adam A1 - Finisguerra, Alessandra A1 - Gourine, Alexander V. A1 - Gharabaghi, Alireza A1 - Hasan, Alkomiet A1 - Burger, Andreas M. A1 - Jaramillo, Andrés M. A1 - Mertens, Ann A1 - Majid, Arshad A1 - Verkuil, Bart A1 - Badran, Bashar W. A1 - Ventura-Bort, Carlos A1 - Gaul, Charly A1 - Beste, Christian A1 - Warren, Christopher M. A1 - Quintana, Daniel S. A1 - Hämmerer, Dorothea A1 - Freri, Elena A1 - Frangos, Eleni A1 - Tobaldini, Eleonora A1 - Kaniusas, Eugenijus A1 - Rosenow, Felix A1 - Capone, Fioravante A1 - Panetsos, Fivos A1 - Ackland, Gareth L. A1 - Kaithwas, Gaurav A1 - O'Leary, Georgia H. A1 - Genheimer, Hannah A1 - Jacobs, Heidi I. L. A1 - Van Diest, Ilse A1 - Schoenen, Jean A1 - Redgrave, Jessica A1 - Fang, Jiliang A1 - Deuchars, Jim A1 - Széles, Jozsef C. A1 - Thayer, Julian F. A1 - More, Kaushik A1 - Vonck, Kristl A1 - Steenbergen, Laura A1 - Vianna, Lauro C. A1 - McTeague, Lisa M. A1 - Ludwig, Mareike A1 - Veldhuizen, Maria G. A1 - De Couck, Marijke A1 - Casazza, Marina A1 - Keute, Marius A1 - Bikson, Marom A1 - Andreatta, Marta A1 - D'Agostini, Martina A1 - Weymar, Mathias A1 - Betts, Matthew A1 - Prigge, Matthias A1 - Kaess, Michael A1 - Roden, Michael A1 - Thai, Michelle A1 - Schuster, Nathaniel M. A1 - Montano, Nicola A1 - Hansen, Niels A1 - Kroemer, Nils B. A1 - Rong, Peijing A1 - Fischer, Rico A1 - Howland, Robert H. A1 - Sclocco, Roberta A1 - Sellaro, Roberta A1 - Garcia, Ronald G. A1 - Bauer, Sebastian A1 - Gancheva, Sofiya A1 - Stavrakis, Stavros A1 - Kampusch, Stefan A1 - Deuchars, Susan A. A1 - Wehner, Sven A1 - Laborde, Sylvain A1 - Usichenko, Taras A1 - Polak, Thomas A1 - Zaehle, Tino A1 - Borges, Uirassu A1 - Teckentrup, Vanessa A1 - Jandackova, Vera K. A1 - Napadow, Vitaly A1 - Koenig, Julian T1 - International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020) JF - Frontiers in Human Neuroscience N2 - Given its non-invasive nature, there is increasing interest in the use of transcutaneous vagus nerve stimulation (tVNS) across basic, translational and clinical research. Contemporaneously, tVNS can be achieved by stimulating either the auricular branch or the cervical bundle of the vagus nerve, referred to as transcutaneous auricular vagus nerve stimulation(VNS) and transcutaneous cervical VNS, respectively. In order to advance the field in a systematic manner, studies using these technologies need to adequately report sufficient methodological detail to enable comparison of results between studies, replication of studies, as well as enhancing study participant safety. We systematically reviewed the existing tVNS literature to evaluate current reporting practices. Based on this review, and consensus among participating authors, we propose a set of minimal reporting items to guide future tVNS studies. The suggested items address specific technical aspects of the device and stimulation parameters. We also cover general recommendations including inclusion and exclusion criteria for participants, outcome parameters and the detailed reporting of side effects. Furthermore, we review strategies used to identify the optimal stimulation parameters for a given research setting and summarize ongoing developments in animal research with potential implications for the application of tVNS in humans. Finally, we discuss the potential of tVNS in future research as well as the associated challenges across several disciplines in research and clinical practice. KW - transcutaneous vagus nerve stimulation KW - minimum reporting standards KW - guidelines & recommendations KW - transcutaneous auricular vagus nerve stimulation KW - transcutaneous cervical vagus nerve stimulation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234346 SN - 1662-5161 VL - 14 ER - TY - JOUR A1 - Fauser, Mareike A1 - Weselek, Grit A1 - Hauptmann, Christine A1 - Markert, Franz A1 - Gerlach, Manfred A1 - Hermann, Andreas A1 - Storch, Alexander T1 - Catecholaminergic Innervation of Periventricular Neurogenic Regions of the Developing Mouse Brain JF - Frontiers in Neuroanatomy N2 - The major catecholamines—dopamine (DA) and norepinephrine (NE)—are not only involved in synaptic communication but also act as important trophic factors and might ultimately be involved in mammalian brain development. The catecholaminergic innervation of neurogenic regions of the developing brain and its putative relationship to neurogenesis is thus of pivotal interest. We here determined DA and NE innervation around the ventricular/subventricular zone (VZ/SVZ) bordering the whole ventricular system of the developing mouse brain from embryonic day 14.5 (E14.5), E16.5, and E19.5 until postnatal day zero (P0) by histological evaluation and HPLC with electrochemical detection. We correlated these data with the proliferation capacity of the respective regions by quantification of MCM\(^{2+}\) cells. During development, VZ/SVZ catecholamine levels dramatically increased between E16.5 and P0 with DA levels increasing in forebrain VZ/SVZ bordering the lateral ventricles and NE levels raising in midbrain/hindbrain VZ/SVZ bordering the third ventricle, the aqueduct, and the fourth ventricle. Conversely, proliferating MCM\(^{2+}\) cell counts dropped between E16.5 and E19.5 with a special focus on all VZ/SVZs outside the lateral ventricles. We detected an inverse strong negative correlation of the proliferation capacity in the periventricular neurogenic regions (log-transformed MCM\(^{2+}\) cell counts) with their NE levels (r = −0.932; p < 0.001), but not their DA levels (r = 0.440; p = 0.051) suggesting putative inhibitory effects of NE on cell proliferation within the periventricular regions during mouse brain development. Our data provide the first framework for further demandable studies on the functional importance of catecholamines, particularly NE, in regulating neural stem/progenitor cell proliferation and differentiation during mammalian brain development. KW - brain development KW - ventricular zone KW - catecholamines KW - norepinephrine KW - dopamine KW - neurogenesis Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-212485 VL - 14 ER - TY - THES A1 - Fekete, Stefanie T1 - Therapeutisches Drug Monitoring (TDM) von Kindern und Jugendlichen unter Behandlung mit Tiaprid : eine prospektive naturalistische Beobachtungsstudie T1 - Therapeutic drug monitoring (TDM) of children and adolescents treated with tiapride N2 - Tiaprid wird bei Kindern und Jugendlichen im deutschsprachigen Raum als Mittel der ersten Wahl zur Behandlung von Ticstörungen off-label eingesetzt. Es gilt dabei die generelle Empfehlung, Therapeutischen Drug Monitoring (TDM) bei der Behandlung von Minderjährigen mit Neuro-/Psychopharmaka durchzuführen. Therapeutische Referenzbereiche für Tiaprid sind bisher jedoch nur für erwachsene Patienten mit Chorea Huntington definiert worden (1000 bis 2000 ng/ml) (Hiemke et al., 2011). An ausgewählten Zentren im Rahmen des Kompetenznetzwerks Therapeutisches Drug Monitoring Kinder- und Jugendpsychiatrie (www.tdm-kjp.com) wurden von 2007 bis 2014 standardisiert TDM-Daten erfasst, um den Zusammenhang zwischen Dosis, Serumkonzentration, Wirksamkeit und UAW von Tiaprid zu untersuchen sowie Hinweise auf einen möglichen alters- und diagnosespezifischen therapeutischen Referenzbereich zu generieren. Bei den 49 Patienten (mittleres Alter 12,5 Jahre; 84 % männlich) zeigte sich eine positive Korrelation (r= 0.76; p< .001) zwischen der Dosis (Mittelwert 354 mg) und der Serumkonzentration von Tiaprid (Mittelwert 1324 ng/ml) mit einer ausgeprägten interindividuellen Variabilität, jedoch keine Beziehung zwischen Serumkonzentration und Wirkeffekt (83,3 % profitierten) bzw. UAW in der Gesamtpopulation. Die Auswertung der Verlaufsmessungen von Patienten mit mehreren Messungen der Tiaprid-Serumkonzentration ergab beim dritten Messzeitpunkt eine negative Korrelation zwischen Wirkeffekt und Serumkonzentration (r= -.68; p= .032). Bei Patienten mit Serumkonzentrationen unter 2000 ng/ml wurde ein günstigerer klinischer Effekt dokumentiert als bei solchen mit Konzentrationen oberhalb dieses Wertes. Die ROC-Analyse ergab eine Sensitivität von 86 %, ab einer Konzentration von 618 ng/ml zu respondieren (AUC= .524). Kein Patient litt an einer schweren UAW und nur wenige Patienten unter leichten oder mittelschweren UAW (n=13). Diese Ergebnisse lassen vermuten, dass der untere therapeutische Referenzbereich für jugendliche Patienten mit einer Tic-Störung bei etwa 600 ng/ml liegt und die obere Grenze von 2000 ng/ml auch als Orientierungswert auf Kinder und Jugendliche gelten könnte. Bevor diesbezüglich gültige Empfehlungen für den klinischen Alltag formuliert werden, müssen Studien mit höheren Fallzahlen und mehr kontrollierten Studiendesigns abgewartet werden.  N2 - Background: Tiapride is used off-label as first-line treatment for children and adolescents with tic disorders in German speaking countries. Methods: Standardized TDM data were collected from 2007 to 2014 within the Competence Network Therapeutic Drug Monitoring in Child and Adolescent Psychiatry (www.tdm-kjp.com) to investigate the correlation between dosage, serum concentration, effectiveness and adverse drug reactions (ADRs) of tiapride. Additionally, information about a possible age- and diagnosis-specific therapeutic reference range should be obtained as the therapeutic reference ranges for tiapride are only available for adult patients with chorea Huntington (1000 to 2000 ng/ml). Results: In the 49 paediatric patients (mean age = 12.5 years, 84% male), a positive correlation (r = 0.76; p <.001) was found between tiapride dose (mean = 353.6 mg) and serum concentration (mean = 1324.0 ng/ml) with marked interindividual variability, but no relationship between serum concentration and effect (83.3% profit) nor ADRs. No patient suffered from severe ADRs and only a few patients had mild or moderate ADRs (n = 13). The evaluation of the measurements of patients with multiple measurements of the tiapride serum concentration (N = 10) showed a negative correlation between effect and serum concentration after one year treatment with tiapride (r = -.68, p = .032). A better outcome in patients with serum concentrations below 2000 ng / ml was observed. ROC analysis revealed a sensitivity of 86% from a concentration of 618 ng/ml in regard to the therapeutic response. Discussion: These results suggest that the lower therapeutic reference range in adolescent patients with tic disorders could be about 600 ng/ml and the upper limit of the adult therapeutic reference range of 2000 ng/ml could be a reference point as a guide to children and adolescents in terms of the incidence of ADRs and the expected effect. KW - therapeutic drug monitoring KW - paediatrics KW - tiapride KW - tic disorders KW - children Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173085 ER - TY - GEN A1 - Fekete, Stefanie A1 - Egberts, K. A1 - Preissler, T. A1 - Wewetzer, C. A1 - Mehler-Wex, C. A1 - Romanos, M. A1 - Gerlach, M. T1 - Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride T2 - European Journal of Clinical Pharmacology N2 - Correction to: European Journal of Clinical Pharmacology (2021) 77:163–170 https://doi.org/10.1007/s00228-020-03000-0 KW - Erratum Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-329467 VL - 77 IS - 8 ER - TY - JOUR A1 - Fekete, Stefanie A1 - Egberts, K. A1 - Preissler, T. A1 - Wewetzer, C. A1 - Mehler-Wex, C. A1 - Romanos, M. A1 - Gerlach, M. T1 - Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride JF - European Journal of Clinical Pharmacology N2 - Purpose Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated. Methods Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures. Results In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs. Conclusions This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml). KW - Tourette syndrome KW - therapeutic drug monitoring KW - serum concentration KW - paediatrics KW - pharmacokinetics Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-279893 VL - 77 IS - 2 ER - TY - JOUR A1 - Fekete, Stefanie A1 - Kulpok, Christine A1 - Taurines, Regina A1 - Egberts, Karin A1 - Geissler, Julia A1 - Gerlach, Manfred A1 - Malonga Makosi, Dorothée A1 - König, Jochem A1 - Urschitz, Michael S. A1 - Toni, Irmgard A1 - Neubert, Antje A1 - Romanos, Marcel T1 - Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry JF - Journal of Neural Transmission N2 - Psychotropic drugs are frequently prescribed ‘off-label’ to children and adolescents and carry the risk of serious adverse drug reactions (sADR). We examined the frequency of sADRs of psychotropic drugs in pediatric inpatients and explored their potential preventability through following the recommendations of a web-based pediatric drug information system (PDIS). The potential socio-economic impacts of using this online system is also addressed. Routine clinical data from all inpatients treated in a child and adolescent psychiatry department between January 2017 and December 2018 were retrospectively examined for the occurrence of sADRs as defined by the European Medicines Agency. The preventability of the sADRs was assessed based on the information of the PDIS. Furthermore, the expected prolongation of the hospital stay due to sADRs was calculated as well as the associated treatment costs. The study was supported by the Innovation Fund of the Joint Federal Committee, grant number 01NVF16021. In total, 1036 patients were screened of whom 658 (63.5%) received psychopharmacological treatment. In 53 (8.1%) of these patients 54 sADRs were documented, of which 37 sADRs were identified as potentially preventable through PDIS. Mitigating sADR through PDIS would likely have prevented prolonged hospital stays and conferred considerable savings for health insurance companies. PDIS provides systematic and evidence-based information about pediatric psychopharmacotherapy and helps to prevent prescribing errors. Therefore, PDIS is a useful tool to increase drug therapy safety in child and adolescent psychiatry. Further prospective studies are needed to confirm the results. KW - adverse effects KW - pharmacovigilance KW - drug safety KW - psychotropic drugs KW - mental health Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324817 VL - 130 IS - 1 ER - TY - THES A1 - Frey, Lillien Mara T1 - Furchtgeneralisierung und Attentional Bias bei Kindern und Jugendlichen mit einer Störung des Sozialverhaltens T1 - Fear Generalization And Attentional Bias in Children And Adolescents With Conduct Disorder N2 - Bereits vorangegangene Studien haben zeigen können, dass eine verstärke Generali- sierung von Furcht sowohl bei Erwachsenen, bei denen beispielsweise eine Angststörung oder eine PTSB diagnostiziert wurde, aber auch bei gesunden Kindern eine Rolle spielt. In unserer Studie untersuchten wir eine Gruppe Kinder und Jugendliche (n = 31, m = 25, w = 6; Alter = 13.35 ± 2.03), die eine Störung des Sozialverhaltens aufwiesen, auf die Konditionierbarkeit von Furcht und eine mögliche Furchtgeneralisierung. Diese Gruppe verglichen wir mit einer gesunden Kontrollgruppe (n = 29, m = 11, w = 18; Alter = 14.28 ± 2.43). Als Generalisierungsstimuli verwendeten wir ein Furchtgeneralisierungsparadigma mit zwei Frauengesichtern, die in vier Schritten aneinander angeglichen wurden. Zusätzlich führten wir mit beiden Probandengruppen ein Dot-Probe-Paradigma zur Objektivierung von Aufmerksamkeitsprozessen im Sinne eines Attentional Bias oder Attentional Avoidance mit emotionalen Gesichtern durch. Wir konnten eine erfolgreiche Furchtkonditionierung für beide Gruppen erreichen. Im Vergleich mit der gesunden Kontrollgruppe zeigte die externalisierende Probandengruppe eine verstärke Furchtgeneralisierung. Hinsichtlich der subjektiven Valenz- und Kontingenzratings wurden die Unterschiede besonders deutlich. Eine verstärkte Generalisierungsneigung bei erhöhter Trait-Angst konnten wir nicht finden. Die externalisierende Gruppe zeigte im Vergleich mit neutralen Gesichtern bei den emotionalen Gesichtern insgesamt einen Attentional Bias. Am deutlichsten war dabei eine verstärkte Aufmerksamkeitslenkung hin zu glücklichen Gesichtern festzustellen. Für die gesunde Kontrollgruppe konnten wir keine Besonderheiten bezüglich der Aufmerksamkeitsrichtung finden. Weiterführende Studien sollten mit größ- eren Probandengruppen und nach Geschlecht und Alter gepaarten Probanden durch- geführt werden. Mit externalisierenden Probanden sollte ein Furchtgeneralisierungs- paradigma mit neutralen Stimuli (z.B. Ringe) gewählt werden, um eine subjektive Wertung emotionaler Gesichter bei den Ratings als Störfaktor auszuschließen. Für externalisierende Probanden sollte außerdem die Ausprägung von CU-Traits erfasst und die Dauer der Testung verkürzt oder auf zwei Termine aufgeteilt werden, um eine ausreichende Konzentrationsfähigkeit zu ermöglichen. N2 - Previous studies have already been able to show that increased generalization of fear plays a role both in adults diagnosed with anxiety disorder or PTSD, but also in healthy children. In our study we examined a group of children and adolescents (n = 31, m = 25, f = 6; age = 13.35 ± 2.03) with conduct disorder for possible fear conditioning and overgeneralization of fear. We compared this group with a healthy control group (n = 29, m = 11, f = 18; age = 14.28 ± 2.43). As generalization stimuli we used a fear generalization paradigm with two female faces that were matched in four steps. In addition both groups performed a dot-probe task to objectify attentional processes in terms of attentional bias or attentional avoidance with emotional faces. We were able to achieve successful fear conditioning for both groups. Compared with the healthy control group the externalizing subject group showed increased fear generalization. Regarding the subjective valence and contingency ratings the differences were particularly evident. We could not find an increased generalization tendency for subjects with increased trait anxiety. The externalizing group showed an attentional bias towards emotional faces compared to neutral faces. Most clearly there was an increased attentional bias towards happy faces. For the healthy control group we could not find any particularities regarding attentional bias or avoidance. Further studies should be conducted with larger subject groups and subjects paired by gender and age. With externalizing subjects a fear-generalization paradigm with neutral stimuli (e.g., rings) should be chosen to exclude subjective scoring of emotional faces in the ratings as a confounding factor. For externalizing subjects, the expression of CU traits should also be recorded and the duration of testing should be shortened or divided into two sessions to enable sufficient concentration. KW - Psychische Störung KW - Kind KW - Furchtgeneralisierung KW - Attentional Bias KW - Attentional Avoidance KW - Störung des Sozialverhaltens KW - Verhaltensstörung KW - Jugend KW - Sekundärkrankheit KW - Angststörung Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259746 ER - TY - JOUR A1 - Föcker, Manuel A1 - Timmesfeld, Nina A1 - Bühlmeier, Judith A1 - Zwanziger, Denise A1 - Führer, Dagmar A1 - Grasemann, Corinna A1 - Ehrlich, Stefan A1 - Egberts, Karin A1 - Fleischhaker, Christian A1 - Wewetzer, Christoph A1 - Wessing, Ida A1 - Seitz, Jochen A1 - Herpertz-Dahlmann, Beate A1 - Hebebrand, Johannes A1 - Libuda, Lars T1 - Vitamin D level trajectories of adolescent patients with anorexia nervosa at inpatient admission, during treatment, and at one year follow up: association with depressive symptoms JF - Nutrients N2 - (1) Background: Evidence has accumulated that patients with anorexia nervosa (AN) are at higher risk for vitamin D deficiency than healthy controls. In epidemiologic studies, low 25(OH) vitamin D (25(OH)D) levels were associated with depression. This study analyzed the relationship between 25(OH)D serum levels in adolescent patients and AN and depressive symptoms over the course of treatment. (2) Methods: 25(OH)D levels and depressive symptoms were analyzed in 93 adolescent (in-)patients with AN from the Anorexia Nervosa Day patient versus Inpatient (ANDI) multicenter trial at clinic admission, discharge, and 1 year follow up. Mixed regression models were used to analyze the relationship between 25(OH)D levels and depressive symptoms assessed by the Beck Depression Inventory (BDI-II). (3) Results: Although mean 25(OH)D levels constantly remained in recommended ranges (≥50 nmol/L) during AN treatment, levels decreased from (in)patient admission to 1 year follow up. Levels of 25(OH)D were neither cross-sectionally, prospectively, nor longitudinally associated with the BDI-II score. (4) Conclusions: This study did not confirm that 25(OH)D levels are associated with depressive symptoms in patients with AN. However, increasing risks of vitamin D deficiency over the course of AN treatment indicate that clinicians should monitor 25(OH)D levels. KW - vitamin D KW - supplements KW - anorexia nervosa KW - depressive symptoms KW - adolescents Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242662 SN - 2072-6643 VL - 13 IS - 7 ER - TY - JOUR A1 - Geissler, Julia A1 - Jans, Thomas A1 - Banaschewski, Tobias A1 - Becker, Katja A1 - Renner, Tobias A1 - Brandeis, Daniel A1 - Döpfner, Manfred A1 - Dose, Christina A1 - Hautmann, Christopher A1 - Holtmann, Martin A1 - Jenkner, Carolin A1 - Millenet, Sabina A1 - Romanos, Marcel T1 - Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)-Study protocol of a randomised controlled trial within the consortium ESCAlife JF - Trials N2 - Background: Despite the high persistence rate of attention-deficit/hyperactivity disorder (ADHD) throughout the lifespan, there is a considerable gap in knowledge regarding effective treatment strategies for adolescents with ADHD. This group in particular often shows substantial psychosocial impairment, low compliance and insufficient response to psychopharmacological interventions. Effective and feasible treatments should further consider the developmental shift in ADHD symptoms, comorbidity and psychosocial adversity as well as family dysfunction. Thus, individualised interventions for adolescent ADHD should comprise a multimodal treatment strategy. The randomised controlled ESCAadol study addresses the needs of this patient group and compares the outcome of short-term cognitive behavioural therapy with parent-based telephone-assisted self-help. Methods/design: In step 1, 160 adolescents aged 12 to 17 years with a diagnosis of ADHD will undergo a treatment as usual (TAU) observation phase of 1 month. In step 2, those still severely affected are randomised to the intervention group with an Individualised Modular Treatment Programme (IMTP) or a telephone-assisted self-help programme for parents (TASH) as an active control condition. The IMTP was specifically designed for the needs of adolescent ADHD. It comprises 10 sessions of individual cognitive behavioural therapy with the adolescents and/or the parents, for which participants choose three out of 10 available focus modules (e.g. organisational skills and planning, emotion regulation, problem solving and stress management, dysfunctional family communication). TASH combines a bibliotherapeutic component with 10 counselling sessions for the parents via telephone. Primary outcome is the change in ADHD symptoms in a clinician-rated diagnostic interview. Outcomes are assessed at inclusion into the study, after the TAU phase, after the intervention phase and after a further 12-week follow-up period. The primary statistical analysis will be by intention-to-treat, using linear regression models. Additionally, we will analyse psychometric and biological predictors and moderators of treatment response. Discussion: ESCAadol compares two short-term non-pharmacological interventions as cost-efficient and feasible treatment options for adolescent ADHD, addressing the specific needs and obstacles to treatment success in this group. We aim to contribute to personalised medicine for adolescent ADHD intended to be implemented in routine clinical care. KW - ADHD KW - adolescents KW - attention-deficit/hyperactivity disorder KW - behaviour therapy KW - RCT KW - individualised modular treatment programme KW - telephone-assisted self-help Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176061 VL - 19 IS - 254 ER - TY - JOUR A1 - Geissler, Julia M. A1 - Werner, Elisabeth A1 - Dworschak, Wolfgang A1 - Romanos, Marcel A1 - Ratz, Christoph T1 - German Law Reform Does Not Reduce the Prevalence of Coercive Measures in Residential Institutions for Children, Adolescents, and Young Adults With Intellectual and Developmental Disabilities JF - Frontiers in Psychiatry N2 - Background: Approximately 10% of children, adolescents and young adults with an intellectual and developmental disability (IDD) in Bavaria live in residential institutions. 2015 saw media reports raising suspicions about excessive use of coercive measures (cM) in those institutions. Until a law reform at the end of 2017 made permission from family courts mandatory for cM, their use was governed by parental consent. The REDUGIA project conducted a representative survey comparing cM and their relation to challenging behaviour (cB) and employee stress in Bavaria pre and post reform. Methods: We sent questionnaires to 65 residential institutions for children, adolescents and young adults with IDD in 2017 (pre reform, T1) and 2019 (post reform, T2). To assess changes, we analysed data from all available questionnaire pairs (T1 and T2, N = 43). We calculated paired t-test and correlative analyses concerning the relationship between cB, cM, and employee stress. Results: The number of residents overall (T1: N = 1,661; T2: N = 1,673) and per institution (T1: m = 38.6 ± 32.0; T2: m = 38.9 ± 34.5, p = 0.920) remained stable. We did not see any changes in the Index cB (p = 0.508) or the proportion of residents per institution displaying various types of challenging behaviour (all ps>0.220). There was no change in the Index cM (p = 0.089) or any indicator of employee stress, all ps > 0.323. At follow-up, the Index cB correlated positively with the Index cM (r = 0.519 p < 0.001). Regarding employee stress, the Index cB correlated positively with the frequency of sick leave (r = 0.322, p = 0.037) and physical attacks on employees (r = 0.552, p < 0.001). The Index cM also correlated positively with the frequency of sick leave (r = 0.340, p = 0.028) and physical attacks on employees (r = 0.492, p = 0.001). Discussion: Coercive measures are not a general phenomenon, but are focused on specialised institutions. The law reform did not lead to changes in the number of children, adolescents and young adults with IDD affected by coercive measures in residential institutions in Bavaria. There were still large discrepancies between institutions in the prevalence of challenging behaviour and coercive measures. Coercive measures were associated with challenging behaviour and employee stress. Taken together, findings from REDUGIA emphasise the need to prevent challenging behaviour and thus coercive measures. KW - intellectual disabilities KW - developmental disabilities KW - challenging behaviours KW - employee stress KW - coercive measures KW - residential institutions Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-249030 SN - 1664-0640 VL - 12 ER - TY - JOUR A1 - Geissler, Julia A1 - Werner, Elisabeth A1 - Dworschak, Wolfgang A1 - Romanos, Marcel A1 - Ratz, Christoph T1 - Freiheitsentziehende Maßnahmen in bayerischen Heimeinrichtungen für Kinder, Jugendliche und junge Volljährige mit Intelligenzminderung JF - Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie N2 - Fragestellung: In Bayern leben etwa 10 % aller jungen Menschen mit Intelligenzminderung in Heimeinrichtungen. 2016 wurde in Presseberichten der Vorwurf unzulässiger freiheitsentziehender Maßnahmen formuliert. Im Rahmen des Projekts REDUGIA wurde in bayerischen Heimeinrichtungen eine repräsentative Erhebung zu freiheitsentziehenden Maßnahmen (FeM), herausforderndem Verhalten (hfV) und der Mitarbeiterbelastung (MaB) durchgeführt. Methodik: 65 Einrichtungen für junge Menschen mit Intelligenzminderung in Bayern wurde ein Fragebogen zu strukturellen Gegebenheiten sowie MaB, hfV und FeM zugesendet. Neben deskriptiven Auswertungen wurden korrelative Analysen bzw. Regressionsanalysen zum Zusammenhang zwischen hfV, FeM und MaB durchgeführt. Ergebnisse: Es wurden Daten zu 1839 Personen in 61 Einrichtungen erhoben. 84.3 % der Einrichtungen berichteten geringe Raten an hfV und FeM, während 15.7 % ein gehäuftes Vorkommen von hfV und FeM angaben. Auf n = 1809 Vollzeitäquivalente kam es innerhalb von 14 Tagen zu 639 körperlichen Angriffen durch Bewohner_innen. In 12 Monaten wurden problemverhaltensassoziiert 85 Krankmeldungen sowie 33 Versetzungsanträge/Kündigungen berichtet. Es zeigte sich ein signifikant positiver Zusammenhang zwischen hfV und FeM (R² = .307, F = 21.719, p < .001). Die Mitarbeiterbelastung korrelierte positiv mit hfV (r = .507, p < .001). Schlussfolgerungen: Die Studienbefunde weisen darauf hin, dass hfV sowie FeM bei jungen Menschen mit Intelligenzminderung kein flächendeckendes Phänomen darstellen, sondern sich auf wenige spezialisierte Einrichtungen fokussieren. Mögliche Maßnahmen zur Prävention von Problemverhalten und Freiheitsentzug werden diskutiert. N2 - Objective: In Bavaria, around 10 % of youths with an intellectual disability (ID) live in residential facilities. In 2015, media raised accusations of inadmissible use of coercive measures. The REDUGIA project carried out a representative survey in Bavarian facilities regarding coercive measures (FeM), challenging behavior (hfV), and employee stress (MaB). Method: We sent a questionnaire concerning structural conditions, MaB, hfV and FeM to 65 Bavarian facilities for young people with ID. In addition to preparing descriptive evaluations, we performed correlative and regression analyses concerning the relationship between hfV, FeM, and MaB. Results: We retrieved data from 1,839 subjects in 61 facilities. 84.3 % of facilities reported low rates of hfV and FeM, while 15.7 % reported an increased incidence of hfV and FeM. For n = 1809 full-time position equivalents there were 639 physical attacks by residents over the course of 14 days. We observed 85 instances of sick leave and 33 transfer apllications/resignation associated with hfV. The frequency of hfV predicted the frequency of FeM (R² = 0.307, F = 21.719, p < .001). MaB correlated positively with hfV (r = 0.507, p < .001). Conclusions: The descriptive data indicate that hfV and FeM are not general phenomena but occur mainly in a circumscript number of highly specialized facilities. This emphasizes the need for prevention of hfV and FeM. T2 - Freedom-restricting measures in Bavarian residential facilities for children, adolescents, and young adults with intellectual disabilities KW - Geistige Behinderung KW - herausforderndes Verhalten KW - freiheitsentziehende Maßnahmen KW - Heimeinrichtungen KW - Mitarbeiterbelastung KW - intellectual disability KW - challenging behavior KW - coercive measures KW - residential institutions KW - employee stress Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-244859 SN - 1422-4917 SN - 1664-2880 VL - 49 IS - 4 ER - TY - JOUR A1 - Gerlach, Manfred A1 - Maetzler, Walter A1 - Broich, Karl A1 - Hampel, Harald A1 - Rems, Lucas A1 - Reum, Torsten A1 - Riederer, Peter A1 - Stäffler, Albrecht A1 - Streffer, Johannes A1 - Berg, Daniela T1 - Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics JF - Journal of Neural Transmission N2 - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies. KW - disease progression KW - biomarkers KW - neuroprotection KW - disease-modifying therapies KW - Parkinson’s disease KW - surrogate endpoints KW - drug development Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125375 VL - 119 IS - 1 ER - TY - JOUR A1 - Gerlach, Manfred A1 - Maetzler, Walter A1 - Broich, Karl A1 - Hampel, Harald A1 - Rems, Lucas A1 - Reum, Torsten A1 - Riederer, Peter A1 - Stöffler, Albrecht A1 - Streffer, Johannes A1 - Berg, Daniela T1 - Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics JF - Journal of Neural Transmission N2 - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies. KW - Parkinson’s disease KW - Disease-modifying therapies KW - Neuroprotection KW - Biomarkers KW - Surrogate endpoints KW - Drug development KW - Disease progression Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133856 VL - 119 IS - 1 ER - TY - THES A1 - Gernert [geb. Baranski], Stefanie T1 - Assoziationsuntersuchung zu Neuropeptid Y-Polymorphismen bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung T1 - Association between neuropeptide Y-polymorphims and the attention-deficit/hyperactivity disorder in children and adolescens N2 - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung ist eine der häufigsten psychiatrischen Erkrankung des Kindesalters, die eine hohe Heritabilität aufweist und häufig bis ins Erwachsenenalter persistiert und lebenslang zu sozialen, gesundheitlichen und ökonomischen Problemen führt. Die ADHS tritt bei vielen Patienten in Kombina-tion mit anderen psychiatrischen und nicht-psychiatrischen Erkrankungen auf. In den letzten Jahren rückte zunehmend die häufig zur ADHS komorbid auftretende Adipositas in den Fokus der Forschung. Auf der Suche nach copy number variations in Zusammenhang mit ADHS, wurde eine Duplikation auf Chromosom 7p15 – dem Genlocus des NPY – entdeckt. NPY, ist ein endogenes orexigenes Peptid, welches physiologischerweise die Nahrungsaufnahme stimuliert und neben zahlreichen Effekten, wie Blutdruck- und Knochenregulation, auch in Zusammenhang mit neuropsychiatrischen Erkrankungen gebracht werden konnte. Diese Duplikation auf einem Genort, dessen Produkt für die Regulation von Energiehaushalt und Körpergewicht zuständig ist, bildete die Grundlage, eine Assoziationsuntersuchung zu NPY-Genvarianten und dem Körpergewicht bei Kindern durchzuführen. Untersucht wurden bei 269 an ADHS erkrankten Kindern und 142 gesunden Kontrollkindern die Assoziation zwischen NPY-Genvarianten (rs16147, rs16139, rs5574, rs16124) und ADHS, sowie die Assoziation zwischen NPY-Genvarianten und BMI-Perzentilen bei ADHS. Es ergab sich keine signifikante Assoziation bezüglich der aufgestellten Hypothesen. N2 - The attention-deficit/hyperactivity disorder (ADHD) is one of the most frequent psychiatric disorders in children. It is highly heritable, often persists until adulthood and causes social, economic and health problems. While psychiatric comorbidities of ADHD have been extensively explored, in the last decade mounting evidence pointed to a possible association between ADHD and obesity. In search of copy number variations related to ADHD and this new comorbidity, a duplication on chromosome 7p15 – the gene of Neuropeptide Y (NPY) - has been identified. NPY is an orexigenic peptide, which stimulates food intake and it has also been implicated in other psychiatric diseases. Therefor we performed an association study in a case contol study design including 269 children with ADHD and 142 healthy controls. The objectiv of our investigation was to study the association between four single nucleotid polymorphisms of the NPY- gene (rs16147, rs16139, rs5574, rs16124) and ADHD, and the association between the NPY-polymorphisms and the bmi-percentiles in children with ADHD. Results: No association between the polymorphisms and ADHD in children was found. No association between bmi-percentiles and the polymorphisms was found in children with ADHD. KW - Übergewicht KW - Neuropeptid Y KW - Aufmerksamkeitsdefizit-Syndrom KW - SNP KW - ADHS KW - Kinder und Jugendliche Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-155692 ER - TY - JOUR A1 - Gottschalk, Michael G. A1 - Richter, Jan A1 - Ziegler, Christiane A1 - Schiele, Miriam A. A1 - Mann, Julia A1 - Geiger, Maximilian J. A1 - Schartner, Christoph A1 - Homola, György A. A1 - Alpers, Georg W. A1 - Büchel, Christian A1 - Fehm, Lydia A1 - Fydrich, Thomas A1 - Gerlach, Alexander L. A1 - Gloster, Andrew T. A1 - Helbig-Lang, Sylvia A1 - Kalisch, Raffael A1 - Kircher, Tilo A1 - Lang, Thomas A1 - Lonsdorf, Tina B. A1 - Pané-Farré, Christiane A. A1 - Ströhle, Andreas A1 - Weber, Heike A1 - Zwanzger, Peter A1 - Arolt, Volker A1 - Romanos, Marcel A1 - Wittchen, Hans-Ulrich A1 - Hamm, Alfons A1 - Pauli, Paul A1 - Reif, Andreas A1 - Deckert, Jürgen A1 - Neufang, Susanne A1 - Höfler, Michael A1 - Domschke, Katharina T1 - Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes JF - Translational Psychiatry N2 - Preclinical studies point to a pivotal role of the orexin 1 (OX1) receptor in arousal and fear learning and therefore suggest the HCRTR1 gene as a prime candidate in panic disorder (PD) with/without agoraphobia (AG), PD/AG treatment response, and PD/AG-related intermediate phenotypes. Here, a multilevel approach was applied to test the non-synonymous HCRTR1 C/T Ile408Val gene variant (rs2271933) for association with PD/AG in two independent case-control samples (total n = 613 cases, 1839 healthy subjects), as an outcome predictor of a six-weeks exposure-based cognitive behavioral therapy (CBT) in PD/AG patients (n = 189), as well as with respect to agoraphobic cognitions (ACQ) (n = 483 patients, n = 2382 healthy subjects), fMRI alerting network activation in healthy subjects (n = 94), and a behavioral avoidance task in PD/AG pre- and post-CBT (n = 271). The HCRTR1 rs2271933 T allele was associated with PD/AG in both samples independently, and in their meta-analysis (p = 4.2 × 10−7), particularly in the female subsample (p = 9.8 × 10−9). T allele carriers displayed a significantly poorer CBT outcome (e.g., Hamilton anxiety rating scale: p = 7.5 × 10−4). The T allele count was linked to higher ACQ sores in PD/AG and healthy subjects, decreased inferior frontal gyrus and increased locus coeruleus activation in the alerting network. Finally, the T allele count was associated with increased pre-CBT exposure avoidance and autonomic arousal as well as decreased post-CBT improvement. In sum, the present results provide converging evidence for an involvement of HCRTR1 gene variation in the etiology of PD/AG and PD/AG-related traits as well as treatment response to CBT, supporting future therapeutic approaches targeting the orexin-related arousal system. KW - human behaviour KW - molecular neuroscience KW - personalized medicine KW - predictive markers KW - psychiatric disorders Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227479 VL - 9 ER - TY - THES A1 - Gräfe, Catherin T1 - Familienuntersuchung bei Kindern und Jugendlichen mit ADHS - Unterschiede der DSM-IV Subtypen bezüglich Komorbidität, familiärer Belastung und Krankheitsbeginn T1 - Family-Investigation of Children and Adolescent with ADHD - Differences between DSM-IV Subtypes with regard to Comorbidity, Family History and Age of Onset N2 - Im Rahmen der vorliegenden Arbeit wurden Unterschiede zwischen dem vorwiegend unaufmerksamen und dem kombinierten Subtyp nach DSM-IV anhand von Familien, in denen mindestens zwei Kinder von ADHS betroffen sind, untersucht. Die familiäre Betroffenheit, Art und Anzahl der komorbiden Störungen sowie der Diagnosezeitpunkt wurden bezüglich der Unterschiede zwischen den Subtypen analysiert. Weiterhin wurden epidemiologische und soziodemographische Merkmale beschrieben. Methodik: Im Rahmen einer Multicenterstudie wurden 250 Kinder sowie deren Eltern aus 116 Familien untersucht. ADHS und Komorbiditäten wurden anhand des K-SADS-PL und DIKJ erhoben. Bei den Eltern wurde ADHS anhand der Wender-Utah-Rating-Scale (WURS) und der Barkley-Skalen ermittelt. Ergebnisse: Bei 39% der an ADHS erkrankten Kinder und Jugendlichen lag zusätzlich mindestens eine komorbide Störung zum Zeitpunkt der Untersuchung vor. Die Annahme, dass der kombinierte Subtyp mit einer höheren familiären Belastung einhergeht, konnte im Rahmen der Studie nicht bestätigt werden. Verglichen mit den einfachen Subtypen zeigte sich keine stärkere Betroffenheit von Komorbiditäten beim kombinierten Subtyp. Patienten, die vom kombinierten Subtyp betroffen waren, hatten signifikant häufiger komorbide externalisierende Störungen als Patienten, bei denen ein einfacher Subtyp diagnostiziert worden war. Diese Studie bestätigte die Annahme, dass Patienten, bei denen ein unaufmerksamer Subtyp diagnostiziert worden war, signifikant häufiger an komorbiden internalisierenden Störungen litten und sich verglichen mit den anderen Subtypen durch einen späteren Diagnosezeitpunkt auszeichneten. N2 - The aim of this examination was to examine differences between the combined subtype and the inattentive subtype of ADHD in families with affected siblings. Prevalence of ADHD in parents, comorbidity and age of onset were investigated. Epidemiological data and demographic data were analysed. Method: 250 siblings and parents in 116 families were explored within a multicenterstudy. ADHD and comorbidity were evaluated with K-SADS-PL and DIKJ. Parental ADHD was explored with Wender-Utah-Rating Scale (WURS) and Barkley-Skales. Results: 39% of the children with ADHD had at least one additional comorbid diagnose. Parents of children with a combined subtype did not have higher rates of ADHD. The rate of externalizing disorders was significantly higher in children with a combined subtype. Children with an inattentive subtype were examined to have more internalizing comorbidities and an earlier age of onset. KW - ADHS KW - ADHS KW - Familienuntersuchung KW - DSM-IV Subtyp KW - Komorbiditäten KW - ADHD KW - Family-Investigation KW - DSM-IV Subtype KW - Comorbidity Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-57370 ER -